

# Jia H Kao

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3565096/publications.pdf>

Version: 2024-02-01

694  
papers

32,015  
citations

6254

80  
h-index

6996

154  
g-index

728  
all docs

728  
docs citations

728  
times ranked

17562  
citing authors

#	ARTICLE	IF	CITATIONS
1	Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. <i>Hepatology International</i> , 2016, 10, 1-98.	4.2	1,908
2	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 161-176.	8.1	1,619
3	Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. <i>Gastroenterology</i> , 2000, 118, 554-559.	1.3	892
4	Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. <i>Hepatology International</i> , 2012, 6, 531-561.	4.2	874
5	Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. <i>Hepatology International</i> , 2008, 2, 263-283.	4.2	832
6	Global control of hepatitis B virus infection. <i>Lancet Infectious Diseases</i> , The, 2002, 2, 395-403.	9.1	750
7	Hepatitis B Virus Genotype and DNA Level and Hepatocellular Carcinoma: A Prospective Study in Men. <i>Journal of the National Cancer Institute</i> , 2005, 97, 265-272.	6.3	518
8	Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. <i>Gastroenterology</i> , 2003, 124, 327-334.	1.3	499
9	High Levels of Hepatitis B Surface Antigen Increase Risk of Hepatocellular Carcinoma in Patients With Low HBV Load. <i>Gastroenterology</i> , 2012, 142, 1140-1149.e3.	1.3	469
10	Hepatitis B genotypes and the response to interferon therapy. <i>Journal of Hepatology</i> , 2000, 33, 998-1002.	3.7	449
11	The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. <i>Hepatology International</i> , 2020, 14, 889-919.	4.2	422
12	The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo. <i>Molecular Therapy - Nucleic Acids</i> , 2014, 3, e186.	5.1	319
13	All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. <i>Lancet</i> , The, 2014, 384, 1597-1605.	13.7	316
14	Two Decades of Universal Hepatitis B Vaccination in Taiwan: Impact and Implication for Future Strategies. <i>Gastroenterology</i> , 2007, 132, 1287-1293.	1.3	314
15	Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. <i>Liver International</i> , 2005, 25, 472-489.	3.9	313
16	The clinical implications of hepatitis B virus genotype: Recent advances. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 123-130.	2.8	312
17	Hepatitis B viral genotypes: Clinical relevance and molecular characteristics. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002, 17, 643-650.	2.8	289
18	Hepatitis B surface antigen quantification: Why and how to use it in 2011 – A core group report. <i>Journal of Hepatology</i> , 2011, 55, 1121-1131.	3.7	280

#	ARTICLE	IF	CITATIONS
19	High Prevalence and Mapping of Pre-S Deletion in Hepatitis B Virus Carriers With Progressive Liver Diseases. <i>Gastroenterology</i> , 2006, 130, 1153-1168.	1.3	257
20	Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. <i>Gastroenterology</i> , 1996, 111, 1307-1312.	1.3	246
21	Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy. <i>Clinical Microbiology Reviews</i> , 2020, 33, .	13.6	239
22	Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 396-415.	8.1	237
23	Towards an HBV cure: state-of-the-art and unresolved questionsâ€”report of the ANRS workshop on HBV cure. <i>Gut</i> , 2015, 64, 1314-1326.	12.1	234
24	Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. <i>Hepatology</i> , 2013, 57, 441-450.	7.3	227
25	Peginterferon Alfa-2a Plus Ribavirin for the Treatment of Dual Chronic Infection With Hepatitis B and C Viruses. <i>Gastroenterology</i> , 2009, 136, 496-504.e3.	1.3	211
26	Clinical relevance of hepatitis B virus genotype in children with chronic infection and hepatocellular carcinoma. <i>Gastroenterology</i> , 2004, 127, 1733-1738.	1.3	197
27	Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. <i>Journal of Hepatology</i> , 2004, 41, 659-666.	3.7	194
28	APASL consensus statements and recommendation on treatment of hepatitis C. <i>Hepatology International</i> , 2016, 10, 702-726.	4.2	189
29	Absence of infection in breast-fed infants born to hepatitis C virus-infected mothers. <i>Journal of Pediatrics</i> , 1995, 126, 589-591.	1.8	188
30	Hepatitis B Virus Genotypes and Variants. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2015, 5, a021436-a021436.	6.2	188
31	Serum Hepatitis B Surface Antigen Levels Predict Surface Antigen Loss in Hepatitis B e Antigen Seroconverters. <i>Gastroenterology</i> , 2011, 141, 517-525.e2.	1.3	184
32	Percutaneous Ethanol Injection Versus Surgical Resection for the Treatment of Small Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2005, 242, 36-42.	4.2	180
33	Genotypes and Clinical Phenotypes of Hepatitis B Virus in Patients with Chronic Hepatitis B Virus Infection. <i>Journal of Clinical Microbiology</i> , 2002, 40, 1207-1209.	3.9	178
34	Pegylated Interferon-Î±2a plus Ribavirin for Treatment of Naive Asian Patients with Hepatitis C Virus Genotype 1 Infection: A Multicenter, Randomized Controlled Trial. <i>Clinical Infectious Diseases</i> , 2008, 47, 1260-1269.	5.8	177
35	Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. <i>Liver International</i> , 2016, 36, 1755-1764.	3.9	177
36	Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation. <i>Journal of Clinical Investigation</i> , 2018, 128, 668-681.	8.2	167

#	ARTICLE	IF	CITATIONS
37	Possible Role of High-Titer Maternal Viremia in Perinatal Transmission of Hepatitis C Virus. <i>Journal of Infectious Diseases</i> , 1994, 169, 638-641.	4.0	163
38	Role of Hepatitis B Viral Load and Basal Core Promoter Mutation in Hepatocellular Carcinoma in Hepatitis B Carriers. <i>Journal of Infectious Diseases</i> , 2006, 193, 1258-1265.	4.0	163
39	Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis. <i>Gastroenterology</i> , 2019, 156, 635-646.e9.	1.3	162
40	Hepatitis B virus genotypes and spontaneous hepatitis B e antigen seroconversion in Taiwanese hepatitis B carriers. <i>Journal of Medical Virology</i> , 2004, 72, 363-369.	5.0	159
41	Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. <i>Hepatology</i> , 2018, 68, 1298-1307.	7.3	158
42	Global Perspective on the Natural History of Chronic Hepatitis B: Role of Hepatitis B Virus Genotypes A to J. <i>Seminars in Liver Disease</i> , 2013, 33, 097-102.	3.6	154
43	APASL consensus statements and management algorithms for hepatitis C virus infection. <i>Hepatology International</i> , 2012, 6, 409-435.	4.2	152
44	Occult Hepatitis B Virus Infection and Clinical Outcomes of Patients with Chronic Hepatitis C. <i>Journal of Clinical Microbiology</i> , 2002, 40, 4068-4071.	3.9	149
45	Intrafamilial Transmission of Hepatitis C Virus: The Important Role of Infections between Spouses. <i>Journal of Infectious Diseases</i> , 1992, 166, 900-903.	4.0	148
46	Natural history of acute and chronic hepatitis B: The role of HBV genotypes and mutants. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2017, 31, 249-255.	2.4	135
47	Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load. <i>Hepatology</i> , 2012, 55, 68-76.	7.3	130
48	Hepatitis B Virus Genotypes and Hepatocellular Carcinoma in Taiwan. <i>Intervirology</i> , 2003, 46, 400-407.	2.8	125
49	Role of Hepatitis B Virus Precore/Core Promoter Mutations and Serum Viral Load on Noncirrhotic Hepatocellular Carcinoma: A Case-Control Study. <i>Journal of Infectious Diseases</i> , 2006, 194, 594-599.	4.0	125
50	Progress towards elimination goals for viral hepatitis. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 533-542.	17.8	118
51	Diagnosis of hepatitis B virus infection through serological and virological markers. <i>Expert Review of Gastroenterology and Hepatology</i> , 2008, 2, 553-562.	3.0	117
52	Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. <i>Hepatology</i> , 2003, 37, 568-576.	7.3	111
53	Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog. <i>Journal of Gastroenterology</i> , 2013, 48, 13-21.	5.1	106
54	Transmission of occult hepatitis B virus by transfusion to adult and pediatric recipients in Taiwan. <i>Journal of Hepatology</i> , 2006, 44, 39-46.	3.7	105

#	ARTICLE	IF	CITATIONS
55	Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers. <i>Gut</i> , 2015, 64, 292-302.	12.1	105
56	Hepatitis B viral factors in HBeAg-Negative carriers with persistently normal serum alanine aminotransferase levels. <i>Hepatology</i> , 2007, 45, 1193-1198.	7.3	103
57	Hepatitis B viral genotypes and lamivudine resistance. <i>Journal of Hepatology</i> , 2002, 36, 303-304.	3.7	102
58	Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 415-423.	3.7	102
59	Therapeutic implications of hepatitis B virus genotypes. <i>Liver International</i> , 2005, 25, 1097-1107.	3.9	100
60	Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan. <i>Journal of Pediatrics</i> , 2001, 139, 349-352.	1.8	99
61	Changing disease burden of hepatocellular carcinoma in the Far East and Southeast Asia. <i>Liver International</i> , 2005, 25, 696-703.	3.9	98
62	Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance. <i>Emerging Microbes and Infections</i> , 2014, 3, 1-7.	6.5	98
63	Quantitative hepatitis B core antibody levels in the natural history of hepatitis B virus infection. <i>Clinical Microbiology and Infection</i> , 2015, 21, 197-203.	6.0	98
64	Hepatitis B viral factors and clinical outcomes of chronic hepatitis B. <i>Journal of Biomedical Science</i> , 2008, 15, 137-145.	7.0	97
65	Increased risk of cirrhosis and its decompensation in chronic hepatitis C patients with new-onset diabetes: A nationwide cohort study. <i>Hepatology</i> , 2014, 60, 807-814.	7.3	97
66	Dynamic contrast-enhanced magnetic resonance imaging with Gd-EOB-DTPA for the evaluation of liver fibrosis in chronic hepatitis patients. <i>European Radiology</i> , 2012, 22, 171-180.	4.5	94
67	Superinfection of heterologous hepatitis C virus in a patient with chronic type C hepatitis. <i>Gastroenterology</i> , 1993, 105, 583-587.	1.3	93
68	Modelling NAFLD disease burden in four Asian regionsâ€”2019â€”2030. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 801-811.	3.7	92
69	Effect of Host and Viral Factors on Hepatitis B E Antigen-Positive Chronic Hepatitis B Patients Receiving Pegylated Interferon-Î±2A Therapy. <i>Antiviral Therapy</i> , 2011, 16, 629-637.	1.0	91
70	Pegylated Interferon-Î±2a With or Without Low-Dose Ribavirin for Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Receiving Hemodialysis. <i>Annals of Internal Medicine</i> , 2013, 159, 729.	3.9	91
71	Association of chronic hepatitis B virus infection with insulin resistance and hepatic steatosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 779-782.	2.8	88
72	Basal core promoter T1762/A1764 and precore A1896 gene mutations in hepatitis B surface antigenâ€”positive hepatocellular carcinoma: a comparison with chronic carriers. <i>Liver International</i> , 2007, 27, 1356-1363.	3.9	87

#	ARTICLE	IF	CITATIONS
73	High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C. <i>Liver International</i> , 2008, 28, 271-277.	3.9	86
74	Recent Advances in the Research of Hepatitis B Virus-Related Hepatocellular Carcinoma. <i>Advances in Cancer Research</i> , 2010, 108, 21-72.	5.0	86
75	Role of viral factors in the natural course and therapy of chronic hepatitis B. <i>Hepatology International</i> , 2007, 1, 415-430.	4.2	84
76	GBV-C in the aetiology of fulminant hepatitis. <i>Lancet</i> , The, 1996, 347, 120-121.	13.7	83
77	Clinical and Virological Aspects of Blood Donors Infected with Hepatitis B Virus Genotypes B and C. <i>Journal of Clinical Microbiology</i> , 2002, 40, 22-25.	3.9	83
78	Hepatitis B e Antigen Seroconversion: A Critical Event in Chronic Hepatitis B Virus Infection. <i>Digestive Diseases and Sciences</i> , 2010, 55, 2727-2734.	2.3	83
79	Increased Risk of Cirrhosis and Its Decompensation in Chronic Hepatitis B Patients With Newly Diagnosed Diabetes: A Nationwide Cohort Study. <i>Clinical Infectious Diseases</i> , 2013, 57, 1695-1702.	5.8	83
80	High Level of Hepatitis B Core-Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load. <i>Gastroenterology</i> , 2019, 157, 1518-1529.e3.	1.3	83
81	Risk stratification for hepatitis B virus related hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 10-17.	2.8	82
82	A review of the burden of hepatitis C virus infection in China, Japan, South Korea and Taiwan. <i>Hepatology International</i> , 2015, 9, 378-390.	4.2	82
83	Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B. <i>Antiviral Therapy</i> , 2010, 15, 1133-1139.	1.0	80
84	Treatment of hepatitis C virus infection in patients with end-stage renal disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 228-239.	2.8	80
85	Hepatitis B vaccination and prevention of hepatocellular carcinoma. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2015, 29, 907-917.	2.4	80
86	Impact of Hepatitis D Virus Infection on the Long-Term Outcomes of Patients with Hepatitis B Virus and HIV Coinfection in the Era of Highly Active Antiretroviral Therapy: A Matched Cohort Study. <i>Clinical Infectious Diseases</i> , 2007, 44, 988-995.	5.8	79
87	Evolution of Hepatitis B Serological Markers in HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2007, 45, 1221-1229.	5.8	77
88	Transient Elastography to Assess Hepatic Fibrosis in Hemodialysis Chronic Hepatitis C Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1057-1065.	4.5	77
89	GB virus-C/hepatitis G virus infection in an area endemic for viral hepatitis, chronic liver disease, and liver cancer. <i>Gastroenterology</i> , 1997, 112, 1265-1270.	1.3	76
90	Association of pre-S deletion mutant of hepatitis B virus with risk of hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 1098-1103.	2.8	76

#	ARTICLE	IF	CITATIONS
91	Sarcopenia and chronic liver diseases. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 1229-1244.	3.0	76
92	APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. <i>Hepatology International</i> , 2016, 10, 681-701.	4.2	75
93	Acute exacerbations of chronic hepatitis B are rarely associated with superinfection of hepatitis B virus. <i>Hepatology</i> , 2001, 34, 817-823.	7.3	73
94	Systematic review: chronic viral hepatitis and metabolic derangement. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 216-230.	3.7	73
95	APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation. <i>Hepatology International</i> , 2019, 13, 649-661.	4.2	72
96	Mixed Infections Of Hepatitis C Virus As A Factor In Acute Exacerbations Of Chronic Type C Hepatitis. <i>Journal of Infectious Diseases</i> , 1994, 170, 1128-1133.	4.0	71
97	Risk factors of hepatitis during Anti-tuberculous treatment and implications of hepatitis virus load. <i>Journal of Infection</i> , 2011, 62, 448-455.	3.3	70
98	Pegylated interferon $\alpha$ -2a versus standard interferon $\alpha$ -2a for treatment-naïve dialysis patients with chronic hepatitis C: a randomised study. <i>Gut</i> , 2007, 57, 525-530.	12.1	69
99	2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1135-1157.	1.7	69
100	Transmission of hepatitis C virus in Asia: past and present perspectives. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, E91-6.	2.8	69
101	A prospective study characterizing full-length hepatitis B virus genomes during acute exacerbation. <i>Gastroenterology</i> , 2003, 124, 80-90.	1.3	68
102	Basal core promoter mutant of hepatitis B virus and progression of liver disease in hepatitis B e antigen-negative chronic hepatitis B. <i>Liver International</i> , 2005, 25, 564-570.	3.9	68
103	Hepatitis B virus infection and metabolic syndrome: Fact or fiction?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 14-20.	2.8	68
104	Hepatitis B Virus-related Hepatocellular Carcinoma: Epidemiology and Pathogenic Role of Viral Factors. <i>Journal of the Chinese Medical Association</i> , 2007, 70, 141-145.	1.4	67
105	Prevention of hepatocellular carcinoma in hepatitis B virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 1352-1357.	2.8	67
106	Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients. <i>Gut</i> , 2013, 62, 182.2-184.	12.1	67
107	Distinct Relapse Rates and Risk Predictors After Discontinuing Tenofovir and Entecavir Therapy. <i>Journal of Infectious Diseases</i> , 2018, 217, 1193-1201.	4.0	67
108	Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up. <i>Hepatology</i> , 2013, 57, 2135-2142.	7.3	66



#	ARTICLE	IF	CITATIONS
109	Slow decline of hepatitis B burden in general population: Results from a population-based survey and longitudinal follow-up study in Taiwan. <i>Journal of Hepatology</i> , 2015, 63, 354-363.	3.7	66
110	Permanent Inactivation of HBV Genomes by CRISPR/Cas9-Mediated Non-cleavage Base Editing. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 20, 480-490.	5.1	66
111	Precore/basal core promoter mutants and hepatitis B viral DNA levels as predictors for liver deaths and hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2006, 12, 6620.	3.3	65
112	Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 7243-7248.	7.1	65
113	Serum adiponectin correlates with viral characteristics but not histologic features in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2005, 43, 235-242.	3.7	64
114	Taiwan consensus statement on the management of chronic hepatitis B. <i>Journal of the Formosan Medical Association</i> , 2019, 118, 7-38.	1.7	64
115	Perspectives and control of hepatitis B virus infection in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2015, 114, 901-909.	1.7	63
116	Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study). <i>Gastroenterology</i> , 2022, 162, 757-771.e4.	1.3	63
117	Comparison of Abbott RealTime HCV Genotype II with Versant Line Probe Assay 2.0 for Hepatitis C Virus Genotyping. <i>Journal of Clinical Microbiology</i> , 2015, 53, 1754-1757.	3.9	62
118	On-Treatment Low Serum HBV RNA Level Predicts Initial Virological Response in Chronic Hepatitis B Patients Receiving Nucleoside Analogue Therapy. <i>Antiviral Therapy</i> , 2015, 20, 369-375.	1.0	61
119	Hepatitis C virus infection in Taiwan: Past, present, and future. <i>Journal of the Formosan Medical Association</i> , 2016, 115, 65-66.	1.7	61
120	Molecular Epidemiology of Hepatitis B Virus. <i>Korean Journal of Internal Medicine</i> , 2011, 26, 255.	1.7	61
121	Transient immunoglobulin M antibody response to hepatitis C virus capsid antigen in posttransfusion hepatitis C: putative serological marker for acute viral infection.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1992, 89, 5971-5975.	7.1	60
122	Least microtransfusion from mother to fetus in elective cesarean delivery. <i>Obstetrics and Gynecology</i> , 1996, 87, 244-248.	2.4	60
123	Secular trend of the viral genotype distribution in children with chronic hepatitis B virus infection after universal infant immunization. <i>Hepatology</i> , 2011, 53, 429-436.	7.3	60
124	Molecular Mechanism and Treatment of Viral Hepatitis-Related Liver Fibrosis. <i>International Journal of Molecular Sciences</i> , 2014, 15, 10578-10604.	4.1	60
125	2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1019-1040.	1.7	60
126	Chronic hepatitis C without anti-hepatitis C antibodies by second-generation assay. <i>Digestive Diseases and Sciences</i> , 1996, 41, 161-165.	2.3	58



#	ARTICLE	IF	CITATIONS
127	Hepatitis B post-partum e antigen clearance in hepatitis B carrier mothers: Correlation with viral characteristics. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006, 21, 605-609.	2.8	58
128	No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection: Table 1.. <i>Clinical Infectious Diseases</i> , 2016, 63, ciw507.	5.8	58
129	Clinical Manifestations and Outcomes of Patients with Sarcomatoid Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 69, 209-221.	7.3	58
130	Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy. <i>Journal of Infectious Diseases</i> , 2020, 221, 389-399.	4.0	58
131	Serum microRNA-122 level correlates with virologic responses to pegylated interferon therapy in chronic hepatitis C. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 7844-7849.	7.1	57
132	Assessing the Durability of Entecavir-Treated Hepatitis B Using Quantitative HBsAg. <i>American Journal of Gastroenterology</i> , 2016, 111, 1286-1294.	0.4	57
133	Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 3719-3724.	7.1	56
134	Impact of hepatitis B virus infection on metabolic profiles and modifying factors. <i>Journal of Viral Hepatitis</i> , 2012, 19, e48-57.	2.0	56
135	Noninvasive tests for the prediction of significant hepatic fibrosis in hepatitis C virus carriers with persistently normal alanine aminotransferases. <i>Liver International</i> , 2006, 26, 1087-1094.	3.9	55
136	Phylogenetic Analysis of GB Virus C: Comparison of Isolates from Africa, North America, and Taiwan. <i>Journal of Infectious Diseases</i> , 1996, 174, 410-413.	4.0	54
137	Quasispecies of Hepatitis C Virus and Genetic Drift of the Hypervariable Region in Chronic Type C Hepatitis. <i>Journal of Infectious Diseases</i> , 1995, 172, 261-264.	4.0	53
138	Systematic Review: Impact of Interferon-based Therapy on HCV-related Hepatocellular Carcinoma. <i>Scientific Reports</i> , 2015, 5, 9954.	3.3	53
139	New perspectives of biomarkers for the management of chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2016, 22, 423-431.	8.9	52
140	Low incidence of hepatitis C virus transmission between spouses: A prospective study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, 391-395.	2.8	51
141	Elevation of serum aminotransferase activity increases risk of carotid atherosclerosis in patients with nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 1411-1416.	2.8	51
142	Serum Hepatitis B Virus-DNA Levels Correlate With Long-term Adverse Outcomes in Spontaneous Hepatitis B e Antigen Seroconverters. <i>Journal of Infectious Diseases</i> , 2012, 205, 54-63.	4.0	51
143	MAGELLAN-2: safety and efficacy of glecaprevir/pibrentasvir in liver or renal transplant adults with chronic hepatitis C genotype 1 infection. <i>Journal of Hepatology</i> , 2017, 66, S90-S91.	3.7	51
144	Genotypes of Hepatitis C Virus in Taiwan and the Progression of Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 1995, 21, 233-237.	2.2	50

#	ARTICLE	IF	CITATIONS
145	Hepatitis B virus variants in patients receiving lamivudine treatment with breakthrough hepatitis evaluated by serial viral loads and full-length viral sequences. <i>Hepatology</i> , 2001, 34, 583-589.	7.3	50
146	Secular trend of age-specific prevalence of hepatitis B surface and e antigenemia in pregnant women in Taiwan. <i>Journal of Medical Virology</i> , 2003, 69, 466-470.	5.0	50
147	Hepatitis B genotypes correlate with tumor recurrence after curative resection of hepatocellular carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2004, 2, 64-71.	4.4	50
148	IL-28B predicts response to chronic hepatitis C therapy – fine-mapping and replication study in Asian populations. <i>Journal of General Virology</i> , 2011, 92, 1071-1081.	2.9	50
149	Higher lifetime chance of spontaneous surface antigen loss in hepatitis B carriers with genotype C infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 949-960.	3.7	49
150	Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals. <i>Journal of Hepatology</i> , 2020, 72, 839-846.	3.7	49
151	Prevalence and Implication of a Newly Identified Infectious Agent (SEN Virus) in Taiwan. <i>Journal of Infectious Diseases</i> , 2002, 185, 389-392.	4.0	48
152	Young Chronic Hepatitis B Patients With Nucleos(t)ide Analogue-induced Hepatitis B e Antigen Seroconversion Have a Higher Risk of HBV Reactivation. <i>Journal of Infectious Diseases</i> , 2012, 206, 1521-1531.	4.0	47
153	Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion. <i>Hepatology</i> , 2013, 57, 934-943.	7.3	47
154	Host Genetic Factors Affecting Spontaneous HBsAg Seroclearance in Chronic Hepatitis B Patients. <i>PLoS ONE</i> , 2013, 8, e53008.	2.5	47
155	HBsAg Profiles in Patients Receiving Peginterferon Alfa-2a plus Ribavirin for the Treatment of Dual Chronic Infection with Hepatitis B and C Viruses. <i>Journal of Infectious Diseases</i> , 2010, 202, 86-92.	4.0	46
156	Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management. <i>Hepatology International</i> , 2013, 7, 316-326.	4.2	46
157	Increased risk of hepatocellular carcinoma in chronic hepatitis C patients with new onset diabetes: a nationwide cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 902-911.	3.7	46
158	Asymptomatic chronic hepatitis B virus infection does not increase the risk of diabetes mellitus: A ten-year observation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 1420-1425.	2.8	45
159	Risk Stratification of Hepatocellular Carcinoma in Hepatitis B Virus e Antigen-Negative Carriers by Combining Viral Biomarkers. <i>Journal of Infectious Diseases</i> , 2013, 208, 584-593.	4.0	45
160	Significance of definitions of relapse after discontinuation of oral antivirals in HBeAg-negative chronic hepatitis B. <i>Hepatology</i> , 2018, 68, 415-424.	7.3	45
161	APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis. <i>Hepatology International</i> , 2022, 16, 1-23.	4.2	45
162	Hepatitis B vaccination: to boost or not to boost?. <i>Lancet</i> , The, 2005, 366, 1337-1338.	13.7	44

#	ARTICLE	IF	CITATIONS
163	Review article: novel therapies for hepatitis B virus cure “ advances and perspectives. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 213-222.	3.7	44
164	Fibrosis-4 Index Helps Identify HBV Carriers With the Lowest Risk of Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , 2017, 112, 1564-1574.	0.4	44
165	Genotypic dominance and novel recombinations in HBV genotype B and C co-infected intravenous drug users. <i>Journal of Medical Virology</i> , 2004, 73, 13-22.	5.0	43
166	<sc>HB</sc>Ag<sc>eAg</sc>-positive chronic hepatitis B: why do I treat my patients with pegylated interferon?. <i>Liver International</i> , 2014, 34, 112-119.	3.9	43
167	Hepatitis B Virus Reactivation in Patients Receiving Interferon-Free Direct-Acting Antiviral Agents for Chronic Hepatitis C Virus Infection. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx028.	0.9	43
168	Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1290-1300.	3.7	43
169	HEV superinfection accelerates disease progression in patients with chronic HBV infection and increases mortality in those with cirrhosis. <i>Journal of Hepatology</i> , 2020, 72, 1105-1111.	3.7	43
170	APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients. <i>Hepatology International</i> , 2021, 15, 833-851.	4.2	43
171	Prevalence and implication of TT virus infection: Minimal role in patients with non-A-E hepatitis in Taiwan. , 1999, 59, 307-312.		42
172	Precore/core promoter mutations and genotypes of hepatitis B virus in chronic hepatitis B patients with fulminant or subfulminant hepatitis. <i>Journal of Medical Virology</i> , 2004, 72, 545-550.	5.0	42
173	Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B. <i>Antiviral Therapy</i> , 2010, 15, 177-184.	1.0	42
174	Treating Immune-tolerant Hepatitis B. <i>Journal of Viral Hepatitis</i> , 2015, 22, 77-84.	2.0	42
175	Interferon $\alpha$ -2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: A randomized study. <i>Hepatology</i> , 2006, 43, 742-749.	7.3	41
176	Vitamin D receptor gene polymorphisms and distinct clinical phenotypes of hepatitis B carriers in Taiwan. <i>Genes and Immunity</i> , 2010, 11, 87-93.	4.1	41
177	Interleukin 28B Genetic Polymorphisms and Viral Factors Help Identify HCV Genotype-1 Patients who Benefit from 24-Week Pegylated Interferon plus Ribavirin Therapy. <i>Antiviral Therapy</i> , 2012, 17, 477-484.	1.0	41
178	Review article: the prevention of hepatitis B-related hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 5-14.	3.7	41
179	Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis B patients: A pilot study. <i>Hepatology</i> , 2002, 36, 1416-1424.	7.3	41
180	Lamivudine treatment for hepatitis B reactivation in HBsAg carriers after organ transplantation: A 4-year experience. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2001, 16, 1001-1008.	2.8	40

#	ARTICLE	IF	CITATIONS
181	Naturally occurring hepatitis B surface gene variants in chronic hepatitis B virus infection: Correlation with viral serotypes and clinical stages of liver disease. <i>Journal of Medical Virology</i> , 2002, 68, 50-59.	5.0	40
182	High prevalence of mixed genotype infections in hepatitis B virus infected intravenous drug users. <i>Journal of Medical Virology</i> , 2004, 74, 536-542.	5.0	40
183	Viral factors correlate with hepatitis B e antigen seroconversion in patients with chronic hepatitis B. <i>Liver International</i> , 2006, 26, 949-955.	3.9	40
184	Reduced Toll-Like Receptor 3 Expression in Chronic Hepatitis B Patients and Its Restoration by Interferon Therapy. <i>Antiviral Therapy</i> , 2013, 18, 877-884.	1.0	40
185	Association Between Serum Level of Hepatitis B Surface Antigen At End of Entecavir Therapy and Risk of Relapse in Antigen-Negative Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1490-1498.e3.	4.4	40
186	Sequence analysis of pre-core/surface and pre-core/core promoter genes of hepatitis B virus in chronic hepatitis C patients with occult HBV infection. <i>Journal of Medical Virology</i> , 2002, 68, 216-220.	5.0	39
187	Hepatitis B genotypes and precore/basal core promoter mutants in HBeAg-negative chronic hepatitis B. <i>Journal of Gastroenterology</i> , 2002, 37, 283-287.	5.1	39
188	Application of Hepatitis B Virus Genotyping and Phylogenetic Analysis in Intrafamilial Transmission of Hepatitis B Virus. <i>Clinical Infectious Diseases</i> , 2005, 41, 1576-1581.	5.8	39
189	Hepatitis B viral factors and treatment responses in chronic hepatitis B. <i>Journal of the Formosan Medical Association</i> , 2013, 112, 302-311.	1.7	39
190	Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. <i>Gut</i> , 2015, 64, 303-311.	12.1	39
191	Hepatitis B virus: new therapeutic perspectives. <i>Liver International</i> , 2016, 36, 85-92.	3.9	39
192	Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy. <i>Antiviral Therapy</i> , 2010, 15, 145-155.	1.0	38
193	Hepatitis C viral infection increases the risk of lymphoid neoplasms: A population-based cohort study. <i>Hepatology</i> , 2016, 63, 721-730.	7.3	38
194	Hepatitis D Virus Genotypes in Intravenous Drug Users in Taiwan: Decreasing Prevalence and Lack of Correlation with Hepatitis B Virus Genotypes. <i>Journal of Clinical Microbiology</i> , 2002, 40, 3047-3049.	3.9	37
195	Serum Biomarkers Predictive of Significant Fibrosis and Cirrhosis in Chronic Hepatitis B. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 705-713.	2.2	37
196	Artificial intelligence in precision medicine in hepatology. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 569-580.	2.8	37
197	Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease. <i>Gut and Liver</i> , 2021, 15, 451-458.	2.9	37
198	Genetic Variability of Hepatitis B virus and Response to Antiviral Therapy. <i>Antiviral Therapy</i> , 2008, 13, 613-624.	1.0	37

#	ARTICLE	IF	CITATIONS
199	A clinicopathologic study of chronic non-A, non-B (type C) hepatitis in Taiwan: comparison between posttransfusion and sporadic patients. <i>Journal of Hepatology</i> , 1994, 21, 244-249.	3.7	36
200	Intrafamilial transmission of hepatitis C virus in hemodialysis patients. <i>Journal of Medical Virology</i> , 1995, 45, 381-385.	5.0	36
201	Pegylated Interferon Alfa-2a Monotherapy for Hemodialysis Patients with Acute Hepatitis C. <i>Clinical Infectious Diseases</i> , 2010, 51, 541-549.	5.8	36
202	East Asia expert opinion on treatment initiation for chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1540-1550.	3.7	36
203	HBV genotypes: Epidemiology and implications regarding natural history. <i>Current Hepatitis Reports</i> , 2006, 5, 5-13.	0.3	35
204	IL-10 promoter gene polymorphisms and sustained response to combination therapy in Taiwanese chronic hepatitis C patients. <i>Digestive and Liver Disease</i> , 2009, 41, 424-430.	0.9	35
205	The clinical manifestations and management of COVID-19-related liver injury. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1016-1018.	1.7	35
206	Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy. <i>Antiviral Therapy</i> , 2009, 14, 45-54.	1.0	35
207	Interferon-alpha reduces insulin resistance and beta-cell secretion in responders among patients with chronic hepatitis B and C. <i>Journal of Endocrinology</i> , 2003, 178, 457-465.	2.6	34
208	Local ablation vs. resection for the treatment of hepatocellular carcinoma. <i>Hepatology</i> , 2006, 43, 373-373.	7.3	34
209	Association of Lipid Profiles With Hepatitis C Viral Load in Chronic Hepatitis C Patients With Genotype 1 or 2 Infection. <i>American Journal of Gastroenterology</i> , 2009, 104, 598-604.	0.4	34
210	The clinical significance of occult hepatitis B transfusion in Taiwan – a look-back study. <i>Transfusion Medicine</i> , 2011, 21, 33-41.	1.1	34
211	Superinfection by homotypic virus in hepatitis C virus carriers: Studies on patients with post-transfusion hepatitis. , 1996, 50, 303-308.		33
212	Molecular epidemiology of hepatitis B viral serotypes and genotypes in taiwan. <i>Journal of Biomedical Science</i> , 2002, 9, 166-170.	7.0	33
213	Metabolic profiles in patients with chronic hepatitis C: a case-control study. <i>Hepatology International</i> , 2008, 2, 250-257.	4.2	33
214	Non-alcoholic fatty liver disease: An emerging liver disease in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2012, 111, 527-535.	1.7	33
215	New Insights into the Evolutionary Rate of Hepatitis B Virus at Different Biological Scales. <i>Journal of Virology</i> , 2015, 89, 3512-3522.	3.4	33
216	The ratio of aminotransferase to platelets is a useful index for predicting hepatic fibrosis in hemodialysis patients with chronic hepatitis C. <i>Kidney International</i> , 2010, 78, 103-109.	5.2	32

#	ARTICLE	IF	CITATIONS
217	GB virus-C/hepatitis G virus infection in prostitutes: Possible role of sexual transmission. <i>Journal of Medical Virology</i> , 1997, 52, 381-384.	5.0	31
218	Interspousal transmission of GB virus-C/hepatitis G virus: A comparison with hepatitis C virus. <i>Journal of Medical Virology</i> , 1997, 53, 348-353.	5.0	31
219	High serum adiponectin correlates with advanced liver disease in patients with chronic hepatitis B virus infection. <i>Hepatology International</i> , 2009, 3, 364-370.	4.2	31
220	Association of metabolic profiles with hepatic fibrosis in chronic hepatitis C patients with genotype 1 or 2 infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 970-977.	2.8	31
221	Fine mapping of hepatitis B virus pre- $\epsilon$ deletion and its association with hepatocellular carcinoma. <i>Liver International</i> , 2012, 32, 1373-1381.	3.9	31
222	Interferon-Based Therapy Decreases Risks of Hepatocellular Carcinoma and Complications of Cirrhosis in Chronic Hepatitis C Patients. <i>PLoS ONE</i> , 2013, 8, e70458.	2.5	31
223	Mechanism of vertical transmission of hepatitis G. <i>Lancet, The</i> , 1996, 347, 1116.	13.7	30
224	Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis B patients: A pilot study. <i>Hepatology</i> , 2002, 36, 1416-1424.	7.3	30
225	Evolution of Hepatitis B virus in an acute hepatitis B patient co-infected with genotypes B and C. <i>Journal of General Virology</i> , 2006, 87, 39-49.	2.9	30
226	Historical epidemiology of hepatitis C virus in select countries—volume 4. <i>Journal of Viral Hepatitis</i> , 2017, 24, 8-24.	2.0	30
227	A novel spontaneous hepatocellular carcinoma mouse model for studying T-cell exhaustion in the tumor microenvironment. , 2018, 6, 144.		30
228	Hepatitis C Virus Cure Rates Are Reduced in Patients With Active but Not Inactive Hepatocellular Carcinoma: A Practice Implication. <i>Clinical Infectious Diseases</i> , 2020, 71, 2840-2848.	5.8	30
229	Influence of Metabolic Syndrome, Viral Genotype and Antiviral Therapy on Superimposed Fatty Liver Disease in Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2005, 10, 405-415.	1.0	30
230	Adiponectin levels among patients with chronic hepatitis B and C infections and in response to IFN-alpha therapy. <i>Liver International</i> , 2005, 25, 752-759.	3.9	29
231	Noninvasive Diagnosis of Hepatic Fibrosis in Patients With Chronic Hepatitis C by Splenic Doppler Impedance Index. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 1199-1206.e1.	4.4	29
232	Esophageal Varices: Noninvasive Diagnosis with Duplex Doppler US in Patients with Compensated Cirrhosis. <i>Radiology</i> , 2008, 248, 132-139.	7.3	29
233	Factors Associated with Progression to Hepatocellular Carcinoma and to Death from Liver Complications in Patients with HBsAg-Positive Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2009, 54, 1337-1346.	2.3	29
234	Hepatitis B virus genotype B has an earlier emergence of lamivudine resistance than genotype C. <i>Antiviral Therapy</i> , 2009, 14, 1157-1163.	1.0	29



#	ARTICLE	IF	CITATIONS
235	Fibrosis index based on four factors better predicts advanced fibrosis or cirrhosis than aspartate aminotransferase/platelet ratio index in chronic hepatitis C patients. <i>Journal of the Formosan Medical Association</i> , 2015, 114, 923-928.	1.7	29
236	Elimination of Hepatitis B: Is It a Mission Possible?. <i>BMC Medicine</i> , 2017, 15, 53.	5.5	29
237	Chronic hepatitis B is associated with an increased risk of B-cell non-Hodgkin's lymphoma and multiple myeloma. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 589-598.	3.7	29
238	Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan. <i>Liver International</i> , 2021, 41, 1265-1277.	3.9	29
239	Hepatitis C and G Virus infections in polytransfused children. <i>European Journal of Pediatrics</i> , 1997, 156, 546-549.	2.7	28
240	TT virus infection in patients with chronic hepatitis B or C: Influence on clinical, histological and virological features. , 2000, 60, 387-392.		28
241	Hepatitis B Virus Basal Core Promoter Mutation and DNA Load Correlate with Expression of Hepatitis B Core Antigen in Patients with Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2009, 199, 742-749.	4.0	28
242	Persistent Hepatitis B Viral Replication in a FVB/N Mouse Model: Impact of Host and Viral Factors. <i>PLoS ONE</i> , 2012, 7, e36984.	2.5	28
243	HBV cure—can we pin our hopes on immunotherapy?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 129-131.	17.8	28
244	Artificial ascites is feasible and effective for difficult-to-ablate hepatocellular carcinoma. <i>Hepatology International</i> , 2015, 9, 514-519.	4.2	28
245	A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection. <i>Liver International</i> , 2016, 36, 1101-1107.	3.9	28
246	Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 710-717.	2.8	28
247	Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment. <i>Gut</i> , 2022, 71, 176-184.	12.1	28
248	TT virus infection in healthy children, children after blood transfusion, and children with non-A to E hepatitis or other liver diseases in Taiwan. <i>Journal of Medical Virology</i> , 2003, 69, 66-71.	5.0	27
249	Hypercholesterolemia in Primary Biliary Cirrhosis. <i>New England Journal of Medicine</i> , 2007, 357, 1561-1562.	27.0	27
250	Pegylated interferon $\alpha$ -2a plus low-dose ribavirin for the retreatment of dialysis chronic hepatitis C patients who relapsed from prior interferon monotherapy. <i>Gut</i> , 2009, 58, 314-316.	12.1	27
251	Serum cytokine/chemokine profiles in acute exacerbation of chronic hepatitis <sc>B</sc>: Clinical and mechanistic implications. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1629-1636.	2.8	27
252	Sofosbuvir-based Interferon-Free Direct Acting Antiviral Regimens for Heart Transplant Recipients With Chronic Hepatitis C Virus Infection. <i>Clinical Infectious Diseases</i> , 2018, 66, 289-292.	5.8	27



#	ARTICLE	IF	CITATIONS
253	Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium. <i>Hepatology International</i> , 2019, 13, 587-598.	4.2	27
254	Overview of Hepatitis B and C Viruses. , 0, , 313-330.		27
255	Low prevalence of hepatitis C virus infection among dentists in Taiwan. <i>Journal of Medical Virology</i> , 1993, 40, 10-13.	5.0	26
256	Immune response to a hepatitis C virus nonstructural protein in chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , 1994, 21, 403-411.	3.7	26
257	Recent advances in the treatment of chronic hepatitis B. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2025-2040.	1.8	26
258	The present and future disease burden of hepatitis C virus infections with today's treatment paradigm: Volume 4. <i>Journal of Viral Hepatitis</i> , 2017, 24, 25-43.	2.0	26
259	Quantification of serum hepatitis B core antibody to predict off-entecavir relapse in patients with chronic hepatitis B. <i>Journal of the Formosan Medical Association</i> , 2018, 117, 915-921.	1.7	26
260	APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment?. <i>Hepatology International</i> , 2019, 13, 103-109.	4.2	26
261	Long-term effectiveness of population-wide multifaceted interventions for hepatocellular carcinoma in Taiwan. <i>Journal of Hepatology</i> , 2021, 75, 132-141.	3.7	26
262	Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: A systematic review, meta-analysis, and expert opinion. <i>Journal of Hepatology</i> , 2022, 77, 1670-1689.	3.7	26
263	High prevalence of occult hepatitis B virus infection in Taiwanese intravenous drug users. <i>Journal of Medical Virology</i> , 2007, 79, 1674-1678.	5.0	25
264	Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 46-50.	2.8	25
265	Adipocytokines and liver fibrosis stages in patients with chronic hepatitis B virus infection. <i>Hepatology International</i> , 2015, 9, 231-242.	4.2	25
266	All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study. <i>Liver International</i> , 2016, 36, 1433-1441.	3.9	25
267	Early acquisition of TT virus in infants: Possible minor role of maternal transmission. <i>Journal of Medical Virology</i> , 2002, 66, 285-290.	5.0	24
268	Improving clinical outcomes of chronic hepatitis B virus infection. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 141-154.	3.0	24
269	Incorporating Serum Level of Hepatitis B Surface Antigen or Omitting Level of Hepatitis B Virus DNA Does not Affect Calculation of Risk for Hepatocellular Carcinoma in Patients Without Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 461-468.e2.	4.4	24
270	Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real-world effectiveness and safety in Taiwan. <i>Liver International</i> , 2020, 40, 758-768.	3.9	24

#	ARTICLE	IF	CITATIONS
271	Three heads are better than two: Hepatitis B core-related antigen as a new predictor of hepatitis B virus-related hepatocellular carcinoma. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 524-534.	8.9	24
272	Evolution of precore/core promoter mutations in hepatitis B carriers with hepatitis B e antigen seroreversion. <i>Journal of Medical Virology</i> , 2004, 74, 237-245.	5.0	23
273	Boceprevir for Chronic HCV Genotype 1 Infection. <i>New England Journal of Medicine</i> , 2011, 365, 176-178.	27.0	23
274	Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin. <i>Antiviral Therapy</i> , 2012, 17, 1059-1067.	1.0	23
275	Urgency to treat patients with chronic hepatitis C in Asia. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 966-974.	2.8	23
276	Generic velpatasvir plus sofosbuvir for hepatitis C virus infection in patients with or without human immunodeficiency virus coinfection. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1690-1698.	3.7	23
277	Revisiting the Stopping Rule for Hepatitis C Genotype 1 Patients Treated with Peginterferon Plus Ribavirin. <i>PLoS ONE</i> , 2012, 7, e52048.	2.5	23
278	Origin of serum hepatitis B virus in acute exacerbation: Comparison with HBV in the liver and from other exacerbation. <i>Hepatology</i> , 2004, 40, 310-317.	7.3	22
279	Clinicopathological differences between hepatitis B viral genotype B- and C-related resectable hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , 2007, 14, 64-69.	2.0	22
280	Milder clinical manifestation of scrub typhus in Kinmen, Taiwan. <i>Journal of the Formosan Medical Association</i> , 2013, 112, 201-207.	1.7	22
281	Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1323-1329.	2.8	22
282	Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study. <i>Scientific Reports</i> , 2018, 8, 13699.	3.3	22
283	Hepatitis C virus load during pregnancy and puerperium. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2000, 107, 1503-1506.	2.3	21
284	Prevalence and clinical implications of HFE gene mutations (C282Y and H63D) in patients with chronic hepatitis B and C in Taiwan. <i>Liver International</i> , 2005, 25, 214-219.	3.9	21
285	The Effects of Metabolic Syndrome Versus Infectious Burden on Inflammation, Severity of Coronary Atherosclerosis, and Major Adverse Cardiovascular Events. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 2532-2537.	3.6	21
286	Increased incidence of gastroesophageal reflux disease in patients with chronic hepatitis B virus infection. <i>Hepatology International</i> , 2010, 4, 585-593.	4.2	21
287	Effects of hepatitis B virus precore and basal core promoter mutations on the expression of viral antigens: genotype B vs C. <i>Journal of Viral Hepatitis</i> , 2011, 18, e482-e490.	2.0	21
288	O166 ALL-ORAL DUAL THERAPY WITH DACLATASVIR AND ASUNAPREVIR IN PATIENTS WITH HCV GENOTYPE 1B INFECTION: PHASE 3 STUDY RESULTS. <i>Journal of Hepatology</i> , 2014, 60, S524-S525.	3.7	21

#	ARTICLE	IF	CITATIONS
289	Liver Gene Expression Profiles Correlate with Virus Infection and Response to Interferon Therapy in Chronic Hepatitis B Patients. <i>Scientific Reports</i> , 2016, 6, 31349.	3.3	21
290	Unmet Needs in Clinical and Basic Hepatitis B Virus Research. <i>Journal of Infectious Diseases</i> , 2017, 216, S750-S756.	4.0	21
291	Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment. <i>Journal of Viral Hepatitis</i> , 2020, 27, 568-575.	2.0	21
292	The metabolic profiles and body composition of lean metabolic associated fatty liver disease. <i>Hepatology International</i> , 2021, 15, 405-412.	4.2	21
293	Antiandrogen Hepatotoxicity in Patients with Chronic Viral Hepatitis. <i>European Urology</i> , 1999, 36, 293-297.	1.9	20
294	Clinical aspects and outcomes of volunteer blood donors testing positive for hepatitis C virus infection in Taiwan: a prospective study. <i>Liver International</i> , 2003, 23, 148-155.	3.9	20
295	Clinical relevance of hepatitis B virus genotypes Ba and Bj in Taiwan. <i>Gastroenterology</i> , 2003, 125, 1916-1917.	1.3	20
296	SEN Virus Infection in Patients with Chronic Hepatitis C: Preferential Coinfection with Hepatitis C Genotype 2a and No Effect on Response to Therapy with Interferon plus Ribavirin. <i>Journal of Infectious Diseases</i> , 2003, 187, 307-310.	4.0	20
297	Appropriate use of interferon for treatment of chronic hepatitis B. <i>Hepatology Research</i> , 2007, 37, S47-S54.	3.4	20
298	Intrathecal Delivery of a Mutant $\mu$ -Opioid Receptor Activated by Naloxone as a Possible Antinociceptive Paradigm. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 334, 739-745.	2.5	20
299	Profound week 4 interferon responsiveness is mandatory for hepatitis C genotype 1 patients with unfavorable IL-28B genotype. <i>Journal of Clinical Virology</i> , 2013, 56, 293-298.	3.1	20
300	Plasma Adipokines and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Virus-Infected Carriers: A Prospective Study in Taiwan. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1659-1671.	2.5	20
301	Reimbursement policies in the Asia-Pacific for chronic hepatitis B. <i>Hepatology International</i> , 2015, 9, 43-51.	4.2	20
302	Benefits of long-term therapy with nucleos(t)ide analogues in treatment-naïve patients with chronic hepatitis B. <i>Current Medical Research and Opinion</i> , 2017, 33, 495-504.	1.9	20
303	Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan. <i>Hepatology International</i> , 2021, 15, 338-349.	4.2	20
304	Serum hepatitis B core-related antigen level stratifies risk of disease progression in chronic hepatitis B patients with intermediate viral load. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 908-918.	3.7	20
305	GB Virus C Infection in Hemodialysis Patients: Molecular Evidence for Nosocomial Transmission. <i>Journal of Infectious Diseases</i> , 1999, 180, 191-194.	4.0	19
306	Clinical relevance of hepatitis B viral genotypes: A case of dΔjΔ vu?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002, 17, 113-115.	2.8	19

#	ARTICLE	IF	CITATIONS
307	Mutations in the NS5A and E2-PePHD regions of hepatitis C virus genotype 1b and response to combination therapy of interferon plus ribavirin. <i>Liver International</i> , 2003, 23, 426-433.	3.9	19
308	Medical Treatment of Fish Bone-Related Liver Abscess. <i>Clinical Infectious Diseases</i> , 2005, 41, 1689-1690.	5.8	19
309	A higher alanine aminotransferase level correlates with earlier hepatitis B e antigen seroconversion in lamivudine-treated chronic hepatitis B patients. <i>Liver International</i> , 2008, 28, 1034-1041.	3.9	19
310	Longitudinal Change of HBsAg in HBeAg-negative Patients with Genotype B or C Infection. <i>PLoS ONE</i> , 2013, 8, e55916.	2.5	19
311	Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa. <i>International Journal of Nanomedicine</i> , 2014, 9, 2051.	6.7	19
312	Fibrosis index predicts cirrhosis risk and liver-related mortality in 2075 patients with chronic HBV infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1480-1489.	3.7	19
313	Risk of hepatocellular carcinoma development after hepatitis C virus eradicated by direct-acting antivirals: Fact or fiction?. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 3-11.	1.7	19
314	Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH). <i>American Journal of Gastroenterology</i> , 2020, 115, 1226-1235.	0.4	19
315	Paradigm shift in the treatment options of hepatocellular carcinoma. <i>Liver International</i> , 2022, 42, 2067-2079.	3.9	19
316	Risk stratification of HBV infection in Asia-Pacific region. <i>Clinical and Molecular Hepatology</i> , 2014, 20, 223.	8.9	19
317	Serotyping of hepatitis C virus in chronic type C hepatitis in Taiwan: Correlation with genotypes. <i>Journal of Gastroenterology</i> , 1996, 31, 224-227.	5.1	18
318	Incidence and clinical presentation of posttransfusion TT virus infection in prospectively followed transfusion recipients: emphasis on its relevance to hepatitis. <i>Transfusion</i> , 2000, 40, 596-601.	1.6	18
319	Recent updates in hepatitis vaccination and the prevention of hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2002, 97, 269-271.	5.1	18
320	Changes of soluble CD26 and CD30 levels correlate with response to interferon plus ribavirin therapy in patients with chronic hepatitis C. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006, 21, 1789-1793.	2.8	18
321	The non-structural 5A protein of hepatitis C virus exhibits genotypic differences in interferon antagonism. <i>Journal of Hepatology</i> , 2008, 49, 899-907.	3.7	18
322	Serum interleukin 6 level correlates with outcomes of acute exacerbation of chronic hepatitis B. <i>Hepatology International</i> , 2012, 6, 591-597.	4.2	18
323	Peginterferon $\hat{\pm}$ in the treatment of chronic hepatitis B. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 995-1006.	3.1	18
324	Reduced Toll-Like Receptor 9 Expression on Peripheral CD14 <sup>+</sup> Monocytes of Chronic Hepatitis B Patients and its Restoration by Effective Therapy. <i>Antiviral Therapy</i> , 2014, 19, 637-643.	1.0	18

#	ARTICLE	IF	CITATIONS
325	Predicting Hepatitis B Virus (HBV) Surface Antigen Seroclearance in HBV e Antigen-Negative Patients With Chronic Hepatitis B: External Validation of a Scoring System. <i>Journal of Infectious Diseases</i> , 2015, 211, 1566-1573.	4.0	18
326	Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase <scp>II</scp> trial. <i>Journal of Viral Hepatitis</i> , 2015, 22, 596-606.	2.0	18
327	Hepatitis B Surface Antigen Loss and Hepatocellular Carcinoma Development in Patients With Dual Hepatitis B and C Infection. <i>Medicine (United States)</i> , 2016, 95, e2995.	1.0	18
328	Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B. <i>Journal of the Formosan Medical Association</i> , 2018, 117, 588-597.	1.7	18
329	Acoustic Radiation Force Impulse US Imaging: Liver Stiffness in Patients with Chronic Hepatitis B with and without Antiviral Therapy. <i>Radiology</i> , 2018, 288, 293-299.	7.3	18
330	Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C. <i>Journal of the Formosan Medical Association</i> , 2019, 118, 1187-1192.	1.7	18
331	Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data. <i>Journal of Microbiology, Immunology and Infection</i> , 2020, 53, 569-577.	3.1	18
332	Hepatitis B reactivation: diagnosis and management. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 565-578.	3.0	18
333	Long-Term Effect of Interferon Plus Ribavirin on Hepatitis B Surface Antigen Seroclearance in Patients Dually Infected with Hepatitis B and C Viruses. <i>PLoS ONE</i> , 2011, 6, e20752.	2.5	18
334	Targeting SHP-1-STAT3 signaling: A promising therapeutic approach for the treatment of cholangiocarcinoma. <i>Oncotarget</i> , 2017, 8, 65077-65089.	1.8	18
335	Early Viral Kinetics during Treatment of Chronic Hepatitis C Virus Infection with Pegylated Interferon Alpha plus Ribavirin in Taiwan. <i>Intervirology</i> , 2007, 50, 310-315.	2.8	17
336	Clinical and Histologic Implications of Delayed Hepatobiliary Enhancement on Magnetic Resonance Imaging With Gadolinium Ethoxybenzyl Diethylenetriaminepentaacetic Acid. <i>Investigative Radiology</i> , 2012, 47, 649-655.	6.2	17
337	Consolidation therapy for HBeAg-positive Asian chronic hepatitis B patients receiving lamivudine treatment: a multicentre study. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2332-8.	3.0	17
338	Strategies to manage hepatitis C virus infection disease burden—Volume 4. <i>Journal of Viral Hepatitis</i> , 2017, 24, 44-63.	2.0	17
339	The effect of interferon-free regimens on health-related quality of life in East Asian patients with chronic hepatitis C. <i>Liver International</i> , 2018, 38, 1179-1187.	3.9	17
340	Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy. <i>Liver Cancer</i> , 2020, 9, 207-220.	7.7	17
341	Sexual transmission of HCV. <i>Lancet, The</i> , 1993, 342, 626.	13.7	16
342	Comparison of two methods for quantification of hepatitis B viral DNA. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002, 14, 423-426.	2.8	16

#	ARTICLE	IF	CITATIONS
343	Higher cut-off index value of immunoglobulin M antibody to hepatitis B core antigen in Taiwanese patients with hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006, 21, 859-862.	2.8	16
344	Lower serum viral loads in young patients with hepatitis-B-virus-related hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , 2007, 14, 153-160.	2.0	16
345	HBV Genotype and Clinical Outcome of Chronic Hepatitis B: Facts and Puzzles. <i>Gastroenterology</i> , 2008, 134, 1272-1273.	1.3	16
346	Severity of fatty liver on ultrasound correlates with metabolic and cardiovascular risk. <i>Kaohsiung Journal of Medical Sciences</i> , 2012, 28, 151-160.	1.9	16
347	Hepatitis B surface antigen level complements viral load in predicting viral reactivation in spontaneous HBeAg seroconverters. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1242-1249.	2.8	16
348	Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients. <i>Scientific Reports</i> , 2017, 7, 3718.	3.3	16
349	A noninvasive diagnosis of hepatic fibrosis by BioFibroScore® in chronic hepatitis C patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 291-297.	2.8	16
350	Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health-related quality of life in East Asian patients with hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1429-1437.	2.0	16
351	Pathologic findings of patients with nonalcoholic fatty liver disease and the impact of concurrent hepatitis B virus infection in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1476-1482.	1.7	16
352	Minimal role of GB virus-C/hepatitis G virus in fulminant and subfulminant hepatitis in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002, 14, 352-357.	2.8	15
353	Daclatasvir/asunaprevir/beclabuvir, all oral, fixed-dose combination for patients with chronic hepatitis C virus genotype 1. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1998-2005.	2.8	15
354	An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE). <i>Journal of Infectious Diseases</i> , 2019, 220, 557-566.	4.0	15
355	Gender Difference in the Association Between Metabolic Factors and Hepatocellular Carcinoma. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa036.	2.9	15
356	Incidence, Factors, and Patient-Level Data for Spontaneous HBsAg Seroclearance: A Cohort Study of 11,264 Patients. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00196.	2.5	15
357	Hepatitis B. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 201-214.	2.2	15
358	Hepatitis B Core-Related Antigen Stratifies the Risk of Liver Cancer in HBeAg-Negative Patients With Indeterminate Phase. <i>American Journal of Gastroenterology</i> , 2022, 117, 748-757.	0.4	15
359	Identification of Humoral Antigenic Determinants in the Hepatitis C Virus NS3 Protein. <i>Journal of Infectious Diseases</i> , 1996, 174, 173-176.	4.0	14
360	Evolution of hepatitis B virus precore/basal core promoter gene in HBeAg-positive chronic hepatitis B patients receiving lamivudine therapy. <i>Liver International</i> , 2004, 24, 9-15.	3.9	14



#	ARTICLE	IF	CITATIONS
361	Typhoid fever and typhoid hepatitis in Taiwan. <i>Epidemiology and Infection</i> , 2005, 133, 1073.	2.1	14
362	Overlap lamivudine treatment in patients with chronic hepatitis B receiving adefovir for lamivudine-resistant viral mutants. <i>Journal of Viral Hepatitis</i> , 2006, 13, 387-395.	2.0	14
363	Subgenotypes of hepatitis B virus genotype C do not correlate with disease progression of chronic hepatitis B in Taiwan. <i>Liver International</i> , 2007, 27, 983-988.	3.9	14
364	A comparison of hepatitis B viral markers of patients in different clinical stages of chronic infection. <i>Hepatology International</i> , 2010, 4, 516-522.	4.2	14
365	Clinical and virological features of occult hepatitis B in patients with HBsAg seroclearance post-treatment or spontaneously. <i>Liver International</i> , 2014, 34, e71-9.	3.9	14
366	Clinical significance and evolution of hepatic HBsAg expression in HBeAg-positive patients receiving interferon therapy. <i>Journal of Gastroenterology</i> , 2014, 49, 356-362.	5.1	14
367	Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis. <i>Liver International</i> , 2016, 36, 954-962.	3.9	14
368	Perspectives on dual hepatitis B and C infection in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2016, 115, 298-305.	1.7	14
369	Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: A cohort study. <i>Hepatology</i> , 2017, 66, 681-681.	7.3	14
370	De novo assembly of highly polymorphic metagenomic data using in situ generated reference sequences and a novel BLAST-based assembly pipeline. <i>BMC Bioinformatics</i> , 2017, 18, 223.	2.6	14
371	Impact of occult hepatitis B on the clinical outcomes of patients with chronic hepatitis C virus infection: A 10-year follow-up. <i>Journal of the Formosan Medical Association</i> , 2017, 116, 697-704.	1.7	14
372	High Serum Lipopolysaccharide-Binding Protein Level in Chronic Hepatitis C Viral Infection Is Reduced by Anti-Viral Treatments. <i>PLoS ONE</i> , 2017, 12, e0170028.	2.5	14
373	Antiviral Therapy in Patients With Chronic Hepatitis C Is Associated With a Reduced Risk of Parkinsonism. <i>Movement Disorders</i> , 2019, 34, 1882-1890.	3.9	14
374	Sofosbuvir-based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1620-1625.	2.8	14
375	Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients. <i>Hepatology International</i> , 2021, 15, 71-81.	4.2	14
376	Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR). <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1151-1162.e6.	4.4	14
377	Hepatitis G Virus Infection in Normal and Prospectively Followed Posttransfusion Children. <i>Pediatric Research</i> , 1997, 42, 784-787.	2.3	14
378	End-of-treatment virologic response does not predict relapse after lamivudine treatment for chronic hepatitis B. <i>World Journal of Gastroenterology</i> , 2004, 10, 3574.	3.3	14



#	ARTICLE	IF	CITATIONS
379	Review article: switching patients with chronic hepatitis B to tenofovir alafenamide—a review of current data. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 921-943.	3.7	14
380	Effects of GB virus-C/hepatitis G virus on hepatitis B and C viremia in multiple hepatitis virus infections. <i>Archives of Virology</i> , 1998, 143, 797-802.	2.1	13
381	Post-partum acute exacerbation of chronic hepatitis in a hepatitis C-carrier mother. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2001, 16, 705-708.	2.8	13
382	Universal Hepatitis B Vaccination: Killing 2 Birds with 1 Stone. <i>American Journal of Medicine</i> , 2008, 121, 1029-1031.	1.5	13
383	Serum p53 gene polymorphisms and severity of hepatitis B or C-related chronic liver diseases in Taiwan. <i>Hepatology International</i> , 2011, 5, 814-821.	4.2	13
384	Peginterferon plus Ribavirin for HIV-infected Patients with Treatment-Naïve Acute or Chronic HCV Infection in Taiwan: A Prospective Cohort Study. <i>Scientific Reports</i> , 2015, 5, 17410.	3.3	13
385	Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis. <i>Scientific Reports</i> , 2017, 7, 1728.	3.3	13
386	Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan. <i>PLoS ONE</i> , 2018, 13, e0209299.	2.5	13
387	Hepatitis B: From control to cure. <i>Journal of the Formosan Medical Association</i> , 2018, 117, 868-870.	1.7	13
388	Recent research progress in hepatocellular carcinoma. <i>Journal of the Formosan Medical Association</i> , 2002, 101, 239-48.	1.7	13
389	Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan. <i>Infectious Diseases and Therapy</i> , 2022, 11, 485-500.	4.0	13
390	GB virus-C/hepatitis G virus infection in Taiwan: A virus that fails to cause a disease?. <i>Journal of Biomedical Science</i> , 1999, 6, 220-225.	7.0	12
391	Influence of Hepatitis C Virus Infection on Soluble Cellular Adhesion Molecules in Hemodialysis Patients. <i>Blood Purification</i> , 2005, 23, 106-112.	1.8	12
392	Selective Transmission of Hepatitis C Virus Quasi Species through a Needlestick Accident in Acute Resolving Hepatitis. <i>Clinical Infectious Diseases</i> , 2006, 42, 1254-1259.	5.8	12
393	Rifaximin Treatment in Hepatic Encephalopathy. <i>New England Journal of Medicine</i> , 2010, 362, 2423-2425.	27.0	12
394	Differential Clinical and Virologic Impact of Hepatitis B Virus Genotypes B and C on HIV-Coinfected Patients Receiving Lamivudine-Containing Highly Active Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2012, 54, 548-555.	5.8	12
395	Association of hepatitis C virus infection and malnutrition-inflammation complex syndrome in maintenance hemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 1176-1183.	0.7	12
396	What can we learn from hepatitis B virus clinical cohorts?. <i>Liver International</i> , 2015, 35, 91-99.	3.9	12

#	ARTICLE	IF	CITATIONS
397	Clinical significance of circulating miR-122 in patients with dual chronic hepatitis B and C virus infection. <i>Hepatology International</i> , 2015, 9, 35-42.	4.2	12
398	Revisiting the Natural History of Chronic HBV Infection. <i>Current Hepatology Reports</i> , 2016, 15, 141-149.	0.9	12
399	Serum viral load at the virological relapse predicts subsequent clinical flares in chronic hepatitis B patients off entecavir therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1512-1519.	2.8	12
400	Genetic variability of hepatitis B virus and response to antiviral therapy. <i>Antiviral Therapy</i> , 2008, 13, 613-24.	1.0	12
401	Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels. <i>Antiviral Therapy</i> , 2009, 14, 203-210.	1.0	12
402	Comparison of Three Different Immunoassays and PCR for the Detection of Hepatitis C Virus Infection in Pregnant Women in Taiwan. <i>Vox Sanguinis</i> , 1993, 65, 117-121.	1.5	11
403	Comparison of Three Different Immunoassays and PCR for the Detection of Hepatitis C Virus Infection in Pregnant Women in Taiwan. <i>Vox Sanguinis</i> , 1993, 65, 117-121.	1.5	11
404	Prominent proliferative response of peripheral blood mononuclear cells to a recombinant non-structural (NS3) protein of hepatitis C virus in patients with chronic hepatitis C. <i>Clinical and Experimental Immunology</i> , 1995, 101, 272-277.	2.6	11
405	GBV-C/HCV infection and aplastic anaemia. <i>Lancet, The</i> , 1996, 348, 1032-1033.	13.7	11
406	Liver and peripheral blood mononuclear cells are not major sites for GB virus-C/hepatitis G virus replication. <i>Archives of Virology</i> , 1999, 144, 2173-2183.	2.1	11
407	Efficacy of consensus interferon in the treatment of chronic hepatitis C. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, 1418-1423.	2.8	11
408	Clinical Impact of GB Virus C Viremia on Patients with HIV Type 1 Infection in the Era of Highly Active Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2007, 44, 584-590.	5.8	11
409	1406 ALISPORIVIR (ALV) PLUS PEG-INTERFERON/RIBAVIRIN (PR) IN HCV G1 TREATMENT-EXPERIENCED PATIENTS ACHIEVES PRIMARY ENDPOINT WITH SUPERIOR EFFICACY AT TREATMENT WEEK 12 COMPARED TO RETREATMENT WITH PR. <i>Journal of Hepatology</i> , 2012, 56, S553-S554.	3.7	11
410	HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients. <i>Journal of the Formosan Medical Association</i> , 2015, 114, 308-313.	1.7	11
411	Association of SCARB1 Gene Polymorphisms with Virological Response in Chronic Hepatitis C Patients Receiving Pegylated Interferon plus Ribavirin Therapy. <i>Scientific Reports</i> , 2016, 6, 32303.	3.3	11
412	How have the recent advances in antiviral therapy impacted the management of virus-related hepatocellular carcinoma?. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 911-919.	1.8	11
413	An update on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Asia. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 759-772.	3.0	11
414	Twelve-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin for non-cirrhotic HCV genotype 1 patients: A phase 2 study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1507-1510.	2.8	11

#	ARTICLE	IF	CITATIONS
415	HCC risk in patients with HBV-related cirrhosis receiving nucleos(t)ide analogues therapy: Is HCC prevented or delayed?. <i>Hepatology</i> , 2018, 67, 1634-1635.	7.3	11
416	Serum Mac-2-Binding Protein Glycosylation Isomer at Virological Remission Predicts Hepatocellular Carcinoma and Death in Chronic Hepatitis B-Related Cirrhosis. <i>Journal of Infectious Diseases</i> , 2020, 221, 589-597.	4.0	11
417	Profile and value of FIB-4 in patients with dual chronic hepatitis C and B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 410-417.	2.8	11
418	Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions. <i>Journal of the Formosan Medical Association</i> , 2019, 118, 556-564.	1.7	11
419	Early antiviral therapy reduces the risk of lymphoma in patients with chronic hepatitis C infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 331-339.	3.7	11
420	Direct comparison of biopsy techniques for hepatic malignancies. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 305-312.	8.9	11
421	Blood-bank screening for hepatitis G. <i>Lancet, The</i> , 1997, 349, 207.	13.7	10
422	Rapid hepatic failure associated with a contracted liver mimicking cirrhosis in a case of nasopharyngeal carcinoma with liver metastasis. <i>Liver</i> , 1996, 16, 283-287.	0.1	10
423	Treatment of Chronic Hepatitis B in Asia-Pacific Countries: Is the Asia-Pacific Consensus Statement being followed?. <i>Antiviral Therapy</i> , 2010, 15, 607-616.	1.0	10
424	Optimal management of hepatocellular carcinoma: Challenges and opportunities. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 1336-1338.	2.8	10
425	Pathogenesis and management of alcoholic liver cirrhosis: a review. <i>Hepatic Medicine: Evidence and Research</i> , 2010, 3, 1.	2.5	10
426	Functional impairment of dendritic cells in patients infected with hepatitis C virus genotype 1 who failed peginterferon plus ribavirin therapy. <i>Journal of Medical Virology</i> , 2011, 83, 1212-1220.	5.0	10
427	Factors affecting the diagnostic accuracy of ultrasonography in assessing the severity of hepatic steatosis. <i>Journal of the Formosan Medical Association</i> , 2014, 113, 249-254.	1.7	10
428	Hepatic necro-inflammation and elevated liver enzymes: Evaluation with MRI perfusion imaging with gadoxetic acid in chronic hepatitis patients. <i>Clinical Radiology</i> , 2014, 69, 473-480.	1.1	10
429	Baseline hepatitis B surface antigen quantitation can predict virologic response in entecavir-treated chronic hepatitis B patients. <i>Journal of the Formosan Medical Association</i> , 2014, 113, 786-793.	1.7	10
430	Successful treatment of chronic hepatitis B and D with pegylated-interferon plus entecavir. <i>Journal of the Formosan Medical Association</i> , 2015, 114, 1140-1141.	1.7	10
431	Pegylated IFN- $\alpha$ suppresses hepatitis C virus by promoting the DAPK-mTOR pathway. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 14799-14804.	7.1	10
432	Looking into the crystal ball: biomarkers for outcomes of HBV infection. <i>Hepatology International</i> , 2016, 10, 99-101.	4.2	10

#	ARTICLE	IF	CITATIONS
433	Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort). <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2884-2892.	2.8	10
434	Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis. <i>Journal of the Formosan Medical Association</i> , 2021, , .	1.7	10
435	Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy. <i>Antiviral Therapy</i> , 2009, 14, 45-54.	1.0	10
436	Lack of Interferon Sensitivity-Determining Region in the Genome of Hepatitis B Virus Genotype Ba. <i>Antiviral Therapy</i> , 2004, 9, 895-903.	1.0	10
437	Absence of extensive genetic heterogeneity of hepatitis C virus in antibody-negative chronic hepatitis C. <i>Journal of Medical Virology</i> , 1996, 49, 87-90.	5.0	9
438	Molecular methods of measurement of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infection: implications for occupational health practice. <i>Occupational and Environmental Medicine</i> , 1999, 56, 730-734.	2.8	9
439	Paratyphoid hepatitis: an emerging clinical entity. <i>American Journal of Medicine</i> , 2002, 113, 257-258.	1.5	9
440	Kinetics of Hepatitis B Virus Reactivation After Chemotherapy: More Questions Than Answers. <i>Gastroenterology</i> , 2006, 131, 1656.	1.3	9
441	Hepatitis C Infection and Metabolic Syndrome. <i>Journal of the Formosan Medical Association</i> , 2010, 109, 403-407.	1.7	9
442	Genomic variation-guided management in chronic hepatitis C. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012, 6, 497-506.	3.0	9
443	IL-21R Gene Polymorphisms and Serum IL-21 Levels Predict Virological Response to Interferon-Based Therapy in Asian Chronic Hepatitis C Patients. <i>Antiviral Therapy</i> , 2013, 18, 1-8.	1.0	9
444	O113 COMBINATION THERAPY WITH PEGINTERFERON ALFA-2a AND A NUCLEOS(T)IDE ANALOGUE FOR HBeAg-POSITIVE CHRONIC HEPATITIS B PATIENTS: RESULTS OF A LARGE, RANDOMISED, MULTICENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY. <i>Journal of Hepatology</i> , 2014, 60, S47.	3.7	9
445	Peginterferon Lambda-1a/Ribavirin with Daclatasvir or Peginterferon Alfa-2a/Ribavirin with Telaprevir for Chronic Hepatitis C Genotype 1b. <i>Journal of Interferon and Cytokine Research</i> , 2016, 36, 635-643.	1.2	9
446	Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection. <i>Hepatology International</i> , 2016, 10, 258-266.	4.2	9
447	Time-varying serum gradient of hepatitis B surface antigen predicts risk of relapses after off-NA therapy. <i>BMC Gastroenterology</i> , 2017, 17, 154.	2.0	9
448	Safety and efficacy at 1 year after switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in chronic HBV patients with risk factors for TDF use. <i>Journal of Hepatology</i> , 2018, 68, S87.	3.7	9
449	Real-world anti-viral treatment decisions among chronic hepatitis C patients in Taiwan: The INITIATE study. <i>Journal of the Formosan Medical Association</i> , 2019, 118, 1014-1023.	1.7	9
450	Peginterferon Alfa-2a (40 kD) Stopping Rules in Chronic Hepatitis B: A Systematic Review and Meta-Analysis of Individual Participant Data. <i>Antiviral Therapy</i> , 2019, 24, 133-140.	1.0	9

#	ARTICLE	IF	CITATIONS
451	Expression of Metastatic Tumor Antigen 1 Splice Variant Correlates With Early Recurrence and Aggressive Features of Hepatitis B Virus-Associated Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 70, 184-197.	7.3	9
452	Quantification of HBV core antibodies may help revisit infectious occult hepatitis B virus. <i>Gut</i> , 2019, 68, 2095.2-2095.	12.1	9
453	Whole genome deep sequencing analysis of viral quasispecies diversity and evolution in HBeAg seroconverters. <i>JHEP Reports</i> , 2021, 3, 100254.	4.9	9
454	Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 575-588.	8.9	9
455	Hepatitis C virus reinfection in patients on haemodialysis after achieving sustained virologic response with antiviral treatment. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, , .	3.7	9
456	Long-term Evolution of Estimated Glomerular Filtration Rate in Patients With Antiviral Treatment for Hepatitis C Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 424-434.e5.	4.4	9
457	Hepatocellular carcinoma after treatment cessation in non-cirrhotic HBeAg-negative chronic hepatitis B: A multicentre cohort study. <i>Liver International</i> , 2022, 42, 541-550.	3.9	9
458	BRIEF COMMUNICATION: Efficacy of ribavirin plus interferon alpha on viraemia of GB virus-C/hepatitis G virus: Comparison with interferon alpha alone. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1998, 13, 1249-1253.	2.8	8
459	GB virus C/hepatitis G virus infection in patients on continuous ambulatory peritoneal dialysis. <i>Nephrology Dialysis Transplantation</i> , 1998, 13, 2914-2919.	0.7	8
460	Subgenotypes of Hepatitis B Virus Genotype C in Taiwan. <i>Journal of Infectious Diseases</i> , 2005, 192, 1308-1309.	4.0	8
461	Mixed hepatitis B virus genotype infections: The more, the worse?. <i>Hepatology</i> , 2006, 44, 770-770.	7.3	8
462	Disease Progression in a Patient with Nonalcoholic Steatohepatitis. <i>Journal of the Formosan Medical Association</i> , 2008, 107, 816-821.	1.7	8
463	Clinical Implications of Hepatitis B Virus Variants. <i>Journal of the Formosan Medical Association</i> , 2010, 109, 321-325.	1.7	8
464	Biphasic Pattern of Depression and Its Predictors during Pegylated Interferon-Based Therapy in Chronic Hepatitis B and C Patients. <i>Antiviral Therapy</i> , 2013, 18, 1-7.	1.0	8
465	Higher adherence with 3-year entecavir treatment than lamivudine or telbivudine in treatment-naïve Taiwanese patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 185-192.	2.8	8
466	A pilot study of add-on oral hypoglycemic agents in treatment-naïve genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin. <i>Journal of the Formosan Medical Association</i> , 2014, 113, 716-721.	1.7	8
467	Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial. <i>Scientific Reports</i> , 2015, 5, 15255.	3.3	8
468	Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis. <i>Scientific Reports</i> , 2020, 10, 9180.	3.3	8

#	ARTICLE	IF	CITATIONS
469	The association of vitamin D with hepatitis B virus replication: Bystander rather than offender. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1634-1641.	1.7	8
470	The impact of cytokine change after hepatitis C virus clearance by direct antiviral agents on the risk of hepatocellular carcinoma. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 965-973.	1.7	8
471	Serum cytokine/chemokine profiles predict hepatitis B reactivation in HBV/HCV co-infected subjects receiving direct-acting antiviral agents. <i>Journal of the Formosan Medical Association</i> , 2021, , .	1.7	8
472	Serum Hepatitis C Virus Titers in the Progression of Type C Chronic Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 1996, 23, 280-283.	2.2	8
473	Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan. <i>Scientific Reports</i> , 2021, 11, 23473.	3.3	8
474	HBV genotypes and outcome of HBV infection. <i>Hepatology</i> , 2005, 41, 216-216.	7.3	7
475	Dynamics of hepatitis B e antigen index ratio correlate with treatment response in chronic hepatitis B patients. <i>Liver International</i> , 2007, 27, 235-239.	3.9	7
476	Hepatitis B virus genotype: What should the clinician know?. <i>Current Hepatitis Reports</i> , 2007, 6, 17-23.	0.3	7
477	Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 102-109.	2.8	7
478	Vascular and hepatic enhancements at MR imaging: comparison of Gd-EOB-DTPA and Gd-DTPA in the same subjects. <i>Clinical Imaging</i> , 2014, 38, 287-291.	1.5	7
479	Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: a randomized trial. <i>Scientific Reports</i> , 2015, 5, 11710.	3.3	7
480	Advanced Hepatic Fibrosis and Steatosis Are Associated With Persistent Alanine Aminotransferase Elevation in Chronic Hepatitis C Patients Negative for Hepatitis C Virus RNA During Pegylated Interferon Plus Ribavirin Therapy. <i>Journal of Infectious Diseases</i> , 2015, 211, 1429-1436.	4.0	7
481	Ritonavir-boosted danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic hepatitis C patients with or without cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1757-1765.	2.8	7
482	One-year weight management lowers lipopolysaccharide-binding protein and its implication in meta-inflammation and liver fibrosis. <i>PLoS ONE</i> , 2018, 13, e0207882.	2.5	7
483	Serine/threonine protein phosphatase 5 is a potential therapeutic target in cholangiocarcinoma. <i>Liver International</i> , 2018, 38, 2248-2259.	3.9	7
484	Role of HBsAg Testing in the Management of Patients with Chronic HBV. <i>Current Hepatology Reports</i> , 2019, 18, 331-341.	0.9	7
485	Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1977-1983.	2.8	7
486	Factors predicting outcomes of hepatitis B-related cirrhosis patients with long-term antiviral therapy. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1483-1489.	1.7	7



#	ARTICLE	IF	CITATIONS
487	Evolution of estimated glomerular filtration rate in human immunodeficiency virus and hepatitis C virus coinfected patients receiving sofosbuvir-based direct-acting antivirals and antiretroviral therapy. <i>Journal of Viral Hepatitis</i> , 2021, 28, 887-896.	2.0	7
488	Relation of Chlamydia pneumoniae infection in Taiwan to angiographically demonstrated coronary artery disease and to the presence of acute myocardial infarction or unstable angina pectoris. <i>American Journal of Cardiology</i> , 2001, 88, 960-963.	1.6	6
489	Molecular assays for hepatitis B virus infection. <i>Hepatology</i> , 2003, 38, 1311-1311.	7.3	6
490	Discontinuation of lamivudine treatment for hepatitis flare after kidney or heart transplantation in hepatitis B surface antigen-positive patients: A retrospective case series. <i>Clinical Therapeutics</i> , 2006, 28, 1327-1334.	2.5	6
491	Human leukocyte antigen-DRB1*1101 correlates with less severe hepatitis in Taiwanese male carriers of hepatitis B virus. <i>Journal of Medical Virology</i> , 2009, 81, 588-593.	5.0	6
492	Interleukin-28B genetic variations and response to interferon-based therapy: Asian perspectives. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 1348-1353.	2.8	6
493	HBV/A and HBV/C genotype predominance among patients with chronic hepatitis B virus infection in Cebu City, Philippines. <i>Hepatology International</i> , 2011, 5, 774-781.	4.2	6
494	Association of IL28B genotypes with metabolic profiles and viral clearance rate in chronic hepatitis C patients. <i>Hepatology International</i> , 2013, 7, 171-179.	4.2	6
495	Fluvastatin helps interferon-based therapy in chronic hepatitis C: Fact or fiction?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 7-9.	2.8	6
496	P1300 EFFICACY AND SAFETY OF DACLATASVIR IN COMBINATION WITH ASUNAPREVIR (DCV+ASV) IN CIRRHOTIC AND NON-CIRRHOTIC PATIENTS WITH HCV GENOTYPE 1B: RESULTS OF THE HALLMARK DUAL STUDY. <i>Journal of Hepatology</i> , 2014, 60, S527-S528.	3.7	6
497	Asunaprevir-containing regimens for the treatment of hepatitis C virus infection. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 9-20.	3.0	6
498	Prevalence and clinical implications of IL28B genotypes in Taiwanese patients with chronic hepatitis C. <i>Journal of the Formosan Medical Association</i> , 2016, 115, 953-960.	1.7	6
499	Treatment of de novo hepatitis C virus-related fibrosing cholestatic hepatitis after orthotopic heart transplantation by ledipasvir and sofosbuvir. <i>Journal of the Formosan Medical Association</i> , 2017, 116, 407-409.	1.7	6
500	HBV markers for HCC prediction: Three heads are better than two?. <i>Journal of Hepatology</i> , 2017, 67, 203-204.	3.7	6
501	Telbivudine therapy for chronic hepatitis B: A journey to identify super-responders and to optimize treatment using the roadmap model. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 73-81.	2.8	6
502	Last Mile to Microelimination of Hepatitis C Virus Infection Among People Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2021, 73, e2172-e2174.	5.8	6
503	High Risk of Clinical Relapse in Patients With Chronic Hepatitis B Virus Infection After Cessation of Prophylactic Antiviral Therapy for Rituximab-Containing Chemotherapy. <i>Journal of Infectious Diseases</i> , 2020, 222, 1345-1352.	4.0	6
504	One-year Fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment. <i>Hepatology International</i> , 2021, 15, 105-113.	4.2	6



#	ARTICLE	IF	CITATIONS
505	Iodized oil computed tomography versus ultrasound-guided radiofrequency ablation for early hepatocellular carcinoma. <i>Hepatology International</i> , 2021, 15, 1247-1257.	4.2	6
506	Detectability and clinical significance of serum hepatitis B virus ribonucleic acid. <i>Hepatobiliary Surgery and Nutrition</i> , 2015, 4, 197-202.	1.5	6
507	Association of Lipid Profiles With Hepatitis C Viral Load in Chronic Hepatitis C Patients With Genotype 1 or 2 Infection. <i>American Journal of Gastroenterology</i> , 2009, 104, 598-604.	0.4	6
508	Influence of metabolic syndrome, viral genotype and antiviral therapy on superimposed fatty liver disease in chronic hepatitis C. <i>Antiviral Therapy</i> , 2005, 10, 405-15.	1.0	6
509	Treatment outcomes of sofosbuvir/velpatasvir/voxilaprevir among NS5A inhibitor-experienced patients with hepatitis C: Real-world data from a multicenter Asian registry. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 1642-1644.	2.8	6
510	Hepatitis G virus in intravenous immunoglobulin. <i>Gastroenterology</i> , 1996, 111, 1399.	1.3	5
511	Mother-to-child HCV transmission. <i>Lancet, The</i> , 2001, 357, 142-143.	13.7	5
512	Interferon-based therapy for dialysis patients with chronic hepatitis C: Progress and challenges (Editorial). <i>Nephrology</i> , 2007, 12, 8-10.	1.6	5
513	Core promoter mutations of hepatitis B virus and hepatocellular carcinoma: Story beyond A1762T/G1764A mutations. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 347-350.	2.8	5
514	Recent Advances in Clinical Application of Gut Hormones. <i>Journal of the Formosan Medical Association</i> , 2010, 109, 859-861.	1.7	5
515	HCV core gene polymorphisms correlate with liver fibrosis but not sustained virological response in patients with genotype 1 infection. <i>Antiviral Therapy</i> , 2011, 16, 227-235.	1.0	5
516	Management of hepatitis C patients with decompensated liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 679-688.	3.0	5
517	Associated factors and clinical implications of serum aminotransferase elevation in scrub typhus. <i>Journal of Microbiology, Immunology and Infection</i> , 2016, 49, 941-946.	3.1	5
518	NOhep: Toward Global Control of Hepatitis B Virus Infection—An Introduction. <i>Journal of Infectious Diseases</i> , 2017, 216, S749-S749.	4.0	5
519	Prevention of mother-to-child transmission: the key of hepatitis B virus elimination. <i>Hepatology International</i> , 2018, 12, 94-96.	4.2	5
520	Nucleos(t)ide analogues in patients with chronic hepatitis B: to stop or not to stop?. <i>Gut</i> , 2019, 68, 2105-2106.	12.1	5
521	Improved quantitative assessment of HBV-associated liver fibrosis using second-harmonic generation microscopy with feature selection. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 12-20.	1.5	5
522	Antiviral therapy against chronic hepatitis C is associated with a reduced risk of oral cancer. <i>International Journal of Cancer</i> , 2020, 147, 901-908.	5.1	5

#	ARTICLE	IF	CITATIONS
523	Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan. Journal of the Formosan Medical Association, 2020, 119, 1871-1875.	1.7	5
524	Combined viral quasispecies diversity and hepatitis B core-related antigen predict off-nucleos(t)ide analog durability in HBeAg-negative patients. Hepatology International, 2021, 15, 582-592.	4.2	5
525	Molecular Epidemiology of Hepatitis B Viral Serotypes and Genotypes in Taiwan. Journal of Biomedical Science, 2002, 9, 166-170.	7.0	5
526	Prevalence, Genotypes and Antibody Titer of Hepatitis C Virus in Pregnant Women in Taiwan. Journal of Obstetrics and Gynaecology (Tokyo, Japan), 1995, 21, 557-562.	0.2	4
527	Hepatitis C Virus Infection and Chronic Active Myocarditis. Circulation, 1998, 98, 1044-1045.	1.6	4
528	Effectiveness of Second and Third Generation Immunoassays for the Detection of Hepatitis C Virus Infection in Pregnant Women. Journal of Obstetrics and Gynaecology Research, 2000, 26, 265-270.	1.3	4
529	Heterogeneity of hereditary persistence of alpha-fetoprotein. Gastroenterology, 2004, 127, 687.	1.3	4
530	Pegylated Interferons for the Treatment of Chronic Hepatitis B. Recent Patents on Anti-infective Drug Discovery, 2006, 1, 85-94.	0.8	4
531	Association of Insulin Resistance with Alanine Aminotransferase Activity in Patients with Nonalcoholic Fatty Liver Disease. Tzu Chi Medical Journal, 2008, 20, 275-279.	1.1	4
532	HBsAg Seroclearance: The More and Earlier, the Better. Gastroenterology, 2009, 136, 1842-1843.	1.3	4
533	Implications of Hepatitis B Virus Genomic Variations on Treatment Outcomes. Current Pharmacogenomics and Personalized Medicine, 2010, 8, 280-288.	0.2	4
534	Hepatitis C virus infection, lipids, and coronary heart disease: A Pandora's box. Hepatology, 2010, 51, 343-343.	7.3	4
535	Aboriginal Taiwanese hepatitis B carriers have more favorable viral factors than Han Chinese carriers. Journal of Medical Virology, 2011, 83, 1326-1331.	5.0	4
536	P0809 : 98% SVR12 in Korean And Taiwanese patients with chronic genotype 2 HCV infection receiving 12 weeks of sofosbuvir plus ribavirin: Results from an international, multicenter phase 3 study. Journal of Hepatology, 2015, 62, S638.	3.7	4
537	Hepatitis B reactivation in patients receiving immunosuppressive therapy: a hidden menace. Hepatology International, 2017, 11, 31-33.	4.2	4
538	Boceprevir-based triple therapy to rescue HCV genotype 1/HBV dually infected patients refractory to peginterferon plus ribavirin combination therapy in Taiwan. Journal of the Formosan Medical Association, 2018, 117, 497-504.	1.7	4
539	NIACE score refines the overall survival of hepatocellular carcinoma by Barcelona clinic liver cancer staging. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 2179-2186.	2.8	4
540	A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): final week 96 efficacy and safety results. Journal of Hepatology, 2020, 73, S67-S68.	3.7	4

#	ARTICLE	IF	CITATIONS
541	Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis. <i>Scientific Reports</i> , 2020, 10, 5372.	3.3	4
542	Clinical manifestations and outcomes of patients with scirrhous hepatocellular carcinoma. <i>Hepatology International</i> , 2021, 15, 472-481.	4.2	4
543	Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 874-885.e4.	4.4	4
544	Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH). <i>Hepatology International</i> , 2021, 15, 1109-1121.	4.2	4
545	Interspousal transmission of GB virusâ€C/hepatitis G virus: A comparison with hepatitis C virus. <i>Journal of Medical Virology</i> , 1997, 53, 348-353.	5.0	4
546	Characterization of metastatic tumor antigen 1 and its interaction with hepatitis B virus X protein in NF-ÎB signaling and tumor progression in a woodchuck hepatocellular carcinoma model. <i>Oncotarget</i> , 2016, 7, 47173-47185.	1.8	4
547	Drug Resistance Profile and Clinical Features for Hepatitis C Patients Experiencing DAA Failure in Taiwan. <i>Viruses</i> , 2021, 13, 2294.	3.3	4
548	Prothrombin induced by vitamin K absence or antagonist-II (PIVKA-II) predicts complete responses of transarterial chemoembolization for hepatocellular carcinoma. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 1579-1587.	1.7	4
549	Detection of divergent hepatitis C virus envelope sequences. <i>Journal of Biomedical Science</i> , 1994, 1, 158-162.	7.0	3
550	The effect of interferon plus ribavirin or interferon alone on the development of hepatocellular carcinoma in non-cirrhotic patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2002, 36, 250.	3.7	3
551	To Genotype or Not To Genotype: Toward an Optimal Tailoring of Treatment of Chronic Hepatitis B. <i>Clinical Infectious Diseases</i> , 2007, 44, 1665-1666.	5.8	3
552	Reply:. <i>Hepatology</i> , 2007, 46, 947-949.	7.3	3
553	Intrafamilial transmission of hepatitis B virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 765-766.	2.8	3
554	Critical analysis of the immune tolerance phase of chronic HBV infection: Natural history and diagnosis. <i>Current Hepatitis Reports</i> , 2008, 7, 5-11.	0.3	3
555	Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Hepatitis C. <i>New England Journal of Medicine</i> , 2009, 361, 1808-1809.	27.0	3
556	Reactivation of hepatitis B virus in an inactive hepatitis B carrier with glucocorticoid pulse therapy. <i>Digestive and Liver Disease</i> , 2009, 41, 322-323.	0.9	3
557	IL28B Genotype on HCV Infection in Asia. <i>Current Hepatitis Reports</i> , 2013, 12, 149-156.	0.3	3
558	Evolution of viral biomarkers in predicting outcomes of chronic hepatitis B patients: From DNA to surface antigen. <i>Tzu Chi Medical Journal</i> , 2013, 25, 75-81.	1.1	3

#	ARTICLE	IF	CITATIONS
559	758 ENTECAVIR PLUS PEGINTERFERON alfa-2a vs. ENTECAVIR ALONE IN THE TREATMENT OF HEPATITIS B e ANTIGEN-POSITIVE CHRONIC HEPATITIS B: AN INTERIM REPORT. <i>Journal of Hepatology</i> , 2013, 58, S308.	3.7	3
560	1421 ALISPORIVIR (ALV) PLUS PEGINTERFERON/RIBAVIRIN (PR) ACHIEVES HIGH SVR12 RATES AMONG NULL RESPONDERS, IL28BCT/TT AND CIRRHOTIC HCVG1 PATIENTS (FUNDAMENTAL STUDY INTERIM ANALYSIS). <i>Journal of Hepatology</i> , 2013, 58, S572.	3.7	3
561	P1118 NO EFFECT OF FALDAPREVIR ON RENAL FUNCTION IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION: POOLED DATA FROM TWO PHASE III TRIALS. <i>Journal of Hepatology</i> , 2014, 60, S451.	3.7	3
562	Efficacy and resistance to telbivudine treatment in chronic hepatitis B patients with favorable predictors: a multicenter study in Taiwan. <i>Hepatology International</i> , 2016, 10, 294-301.	4.2	3
563	Letter: <sc>HB</sc>sAg kinetics&#x2013;guided interferon therapy for chronic hepatitis D. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 480-481.	3.7	3
564	Surveillance of Hepatocellular Carcinoma by Magnetic Resonance Imaging With Liver-Specific Contrast. <i>JAMA Oncology</i> , 2017, 3, 446.	7.1	3
565	The Role of Hepatitis B Surface Antigen in Nucleos(t)ide Analogue Cessation Among Asian Chronic Hepatitis B Patients: Friend or Foe?. <i>Hepatology</i> , 2019, 69, 1843-1843.	7.3	3
566	Genetic variation in <i>FCER1A</i> predicts peginterferon alfa&#x2013;induced hepatitis B surface antigen clearance in East Asian patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1040-1049.	2.0	3
567	Quantification of Hepatitis B Core Antibody Helps Predict Clinical Relapse After Cessation of Nucleos(t)ide Analogues in Chronic Hepatitis B Patients: More Needs to Be Done. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1000-1001.	4.4	3
568	Resistance-associated substitution and ledipasvir/sofosbuvir therapy in Mongolian chronic hepatitis C patients. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 712-719.	1.7	3
569	Towards elimination of viral hepatitis in Taiwan by 2025: In memory of Professor Ding-Shinn Chen (1943&#x2013;2020). <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1247-1248.	1.7	3
570	Relationship between serum gamma-glutamyl transferase level and colorectal adenoma. <i>PLoS ONE</i> , 2020, 15, e0240445.	2.5	3
571	Successful Antiviral Therapy Reduces Risk of Schizophrenia Among Chronic Hepatitis C Patients: A Nationwide Real-World Taiwanese Cohort (T-COACH). <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa397.	0.9	3
572	Both hepatitis A and hepatitis D infections may be associated with more advanced liver disease in patients with chronic hepatitis B. <i>Advances in Digestive Medicine</i> , 2020, , .	0.2	3
573	Long&#x2013;term risk of end&#x2013;stage renal diseases with maintenance dialysis among chronic hepatitis C patients after antiviral therapy in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2247-2254.	2.8	3
574	Investigating the prevalence and clinical effects of hepatitis delta viral infection in Taiwan. <i>Journal of Microbiology, Immunology and Infection</i> , 2021, 54, 901-908.	3.1	3
575	Sofosbuvir/velpatasvir or glecaprevir/pibrentasvir for treating patients with hepatitis C virus reinfection following direct&#x2013;acting antiviral&#x2013;induced sustained virologic response. <i>Advances in Digestive Medicine</i> , 0, , .	0.2	3
576	Pooling data to assess risks and benefits of discontinuing nucleos(t)ide analogs in patients with chronic hepatitis B: challenges and opportunities. <i>Gut</i> , 2022, 71, 1238-1240.	12.1	3

#	ARTICLE	IF	CITATIONS
577	Metastatic tumor antigen 1 contributes to hepatocarcinogenesis posttranscriptionally through RNA-binding function. <i>Hepatology</i> , 2023, 77, 379-394.	7.3	3
578	Lack of interferon sensitivity-determining region in the genome of hepatitis B virus genotype Ba. <i>Antiviral Therapy</i> , 2004, 9, 895-903.	1.0	3
579	Evaluation of Third-Generation Hepatitis C Antibody Assay in Chronic Hepatitis C and Chronic Non-B, Non-C Hepatitis. <i>Viral Immunology</i> , 1995, 8, 135-139.	1.3	2
580	Clinical Significance of Occult Hepatitis B Virus Infection Cannot Be Overlooked. <i>Clinical Infectious Diseases</i> , 2006, 42, 583-584.	5.8	2
581	Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism is associated with choledocholithiasis in Taiwanese patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 1559-1561.	2.8	2
582	Metformin improves sustained virologic response in difficult-to-cure hepatitis C: More questions than answers. <i>Hepatology</i> , 2010, 51, NA-NA.	7.3	2
583	Use of Statins and Gallstone Risk. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 1146.	7.4	2
584	Alanine Aminotransferase, Metabolic Syndrome, and Cardiovascular Disease: A Missing Link?. <i>American Journal of Gastroenterology</i> , 2010, 105, 224.	0.4	2
585	Hepatitis C Virus Infection in Pregnant Women: Detection by Different Anti-HCV Immunoassays and Serum HCV RNA. <i>Asia-Oceania Journal of Obstetrics and Gynaecology</i> , 1994, 20, 13-18.	0.0	2
586	Role of Viral Factors in Modifying Weight-Related Effects on Disease Progression of Chronic Hepatitis C Patients. <i>Gastroenterology</i> , 2010, 138, 788-789.	1.3	2
587	Hepatitis C virus and lipid profiles: more questions than answers?. <i>Hepatology International</i> , 2011, 5, 865-867.	4.2	2
588	Host genetic variants and hepatitis B virologic features in HBeAg-negative hepatitis B carriers with long-term biochemical remission. <i>Hepatology International</i> , 2012, 6, 598-605.	4.2	2
589	Microevolution of the hepatitis B virus genome in hepatitis B antigen-positive carriers: Comparison of genotypes B and C at various immune stages. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 172-177.	2.8	2
590	Clinical evaluation of IntelliPlex™ HCV genotyping kit for hepatitis C virus genotyping. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 94, 344-348.	1.8	2
591	Characteristics of patients with hepatitis C virus infection and antiviral treatment initiation in Taiwan: The MOSAIC study. <i>Kaohsiung Journal of Medical Sciences</i> , 2021, 37, 245-252.	1.9	2
592	Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 1567-1578.	1.7	2
593	Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals. <i>Viruses</i> , 2022, 14, 333.	3.3	2
594	Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels. <i>Antiviral Therapy</i> , 2009, 14, 203-10.	1.0	2

#	ARTICLE	IF	CITATIONS
595	HIV/HCV Coinfection in Taiwan. <i>AIDS Reviews</i> , 2016, 18, 193-197.	1.0	2
596	Letter: hepatic steatosis and fibrosis in chronic hepatitis B—the chicken-and-egg conundrum. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 143-144.	3.7	2
597	Immunoglobulin M antibodies against hepatitis C virus antigens: significance and applications. <i>Gastroenterologia Japonica</i> , 1993, 28, 67-70.	0.3	1
598	Title is missing!. <i>Journal of Pediatrics</i> , 1995, 127, 671.	1.8	1
599	Hepatitis B virus genotypes and core promoter variant. <i>Gastroenterology</i> , 2004, 126, 633.	1.3	1
600	Esomeprazole for Asthma. <i>New England Journal of Medicine</i> , 2009, 361, 206-208.	27.0	1
601	381 SERUM HEPATITIS B VIRUS DNA LEVEL AT ONE YEAR AFTER HEPATITIS B E ANTIGEN SEROCONVERSION PREDICTS SUBSEQUENT HEPATITIS B REACTIVATION. <i>Journal of Hepatology</i> , 2009, 50, S145.	3.7	1
602	Outcomes of HCV treatment: Who does well and who does not?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 846-848.	2.8	1
603	Metabolic syndrome on top of chronic hepatitis B: the more, the worse?. <i>Gut</i> , 2010, 59, 276-277.	12.1	1
604	A Novel Antibody Associated with Autoimmune Pancreatitis. <i>New England Journal of Medicine</i> , 2010, 362, 759-761.	27.0	1
605	Younger age and female sex predict a better therapeutic response in HBeAg-positive chronic hepatitis B patients to entecavir therapy. <i>Advances in Digestive Medicine</i> , 2014, 1, 112-117.	0.2	1
606	Triple Therapy for Hepatitis C Virus Infection in Patients Receiving Hemodialysis. <i>Annals of Internal Medicine</i> , 2014, 160, 581.	3.9	1
607	P0857 : 98% SVR12 in Korean and Taiwanese patients with chronic genotype 1 HCV infection receiving 12 weeks of ledipasvir/sofosbuvir: Results from an international, multicenter phase 3 study. <i>Journal of Hepatology</i> , 2015, 62, S661-S662.	3.7	1
608	Can noninvasive biomarkers replace liver biopsy for chronic hepatitis B?. <i>Hepatology</i> , 2015, 62, 1924-1925.	7.3	1
609	Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials. <i>Annals of Hepatology</i> , 2016, 15, 333-349.	1.5	1
610	Efficacy of entecavir therapy for hepatitis B e-antigen positive chronic hepatitis B patients with prior exposure to interferon or nucleoside/nucleotide analogues. <i>Hepatology Research</i> , 2016, 46, 642-649.	3.4	1
611	Response to Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. <i>Liver International</i> , 2017, 37, 310-311.	3.9	1
612	More viral mutants, less HBsAg clearance? One size may not fit all. <i>Gut</i> , 2017, 66, 1349-1349.	12.1	1



#	ARTICLE	IF	CITATIONS
613	Noninvasive diagnosis of hepatic fibrosis by biofibroscore <sup>Â</sup> ® in patients with chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , 2017, 66, S233-S234.	3.7	1
614	FRI-158-Bone and renal safety are improved in chronic HBV patients switched to tenofovir alafenamide (TAF) after either 2 or 3 years of prior tenofovir disoproxil fumarate (TDF) treatment. <i>Journal of Hepatology</i> , 2019, 70, e457-e458.	3.7	1
615	Editorial: nephrotoxicity and oral anti-viral therapy for HBV-facts or fiction?. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 229-230.	3.7	1
616	Hepatitis C virus genotypes 1-3 infections regulate lipogenic signaling and suppress cholesterol biosynthesis in hepatocytes. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1382-1395.	1.7	1
617	Novel Biomarkers for the Management of Chronic Hepatitis B Virus Infection. , 2021, , 231-250.		1
618	Response to letter to the editor -The impact of cytokine change after hepatitis C virus clearance by direct antiviral agents on the risk of hepatocellular carcinoma. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 1161-1164.	1.7	1
619	What we have learned from COVID-19 pandemic?. <i>Journal of the Formosan Medical Association</i> , 2021, 120, S1-S5.	1.7	1
620	GB Virus-C/Hepatitis G Virus Infection in Taiwan: A Virus That Fails to Cause a Disease?. <i>Journal of Biomedical Science</i> , 1999, 6, 220-225.	7.0	1
621	Management of Hepatitis B in Persons Who Inject Drugs (PWID). <i>Current Hepatology Reports</i> , 2021, 20, 158.	0.9	1
622	Withdrawal of Nucleos(t)ide Analogues in Hepatitis B e Antigen-Negative Patients: An Asian Perspective. <i>Clinical Liver Disease</i> , 2020, 16, 244-248.	2.1	1
623	Letter: elevated HBV DNA predicts poor survival in hepatocellular carcinoma after hepatic resection-authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 203-204.	3.7	1
624	Detection of Divergent Hepatitis C Virus Envelope Sequences. <i>Journal of Biomedical Science</i> , 1994, 1, 158-162.	7.0	0
625	Interspousal transmission of TT virus: Low efficiency and lack of apparent risk factors. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, 1287-1291.	2.8	0
626	Interferon and ribavirin combination therapy clears HCV in hepatitis B and C co-infection patients as effectively as in simple hepatitis C: a pilot study. <i>Journal of Hepatology</i> , 2002, 36, 174.	3.7	0
627	HCV infection in volunteer blood donors in Taiwan: a 6-year follow-up. <i>Journal of Hepatology</i> , 2002, 36, 238.	3.7	0
628	Effects of diabetes on the ED presentation of acute intermittent porphyria. <i>American Journal of Emergency Medicine</i> , 2005, 23, 571-572.	1.6	0
629	Sequential Combination Therapy for Chronic Hepatitis B: More Challenges to Be Tackled. <i>American Journal of Gastroenterology</i> , 2007, 102, 1544-1544.	0.4	0
630	Hepatitis B viral load as a prognostic factor for patients with unresectable hepatocellular carcinoma. <i>Future Virology</i> , 2007, 2, 441-443.	1.8	0



#	ARTICLE	IF	CITATIONS
631	[610] AN OPEN-LABEL, COMPARATIVE, MULTICENTER STUDY OF PEGINTERFERON a-2a PLUS RIBAVIRIN FOR CHRONIC HEPATITIS C/HEPATITIS B CO-INFECTION VERSUS CHRONIC HEPATITIS C MONOINFECTION: AN INTERIM REPORT. <i>Journal of Hepatology</i> , 2007, 46, S231.	3.7	0
632	Viremia Profiles in Hepatitis B Virus Carrier Children With Spontaneous e Antigen Seroconversion: A Case of DÃ©jÃ© Vu?. <i>Gastroenterology</i> , 2007, 133, 1052-1053.	1.3	0
633	APRI-M6 for predicting long-term outcome of chronic hepatitis C patients after interferon-based therapy: More questions than answers. <i>Hepatology</i> , 2007, 45, 1586-1587.	7.3	0
634	Insulin resistance, adipocytokines, and hepatitis C virus infection: A missing link?. <i>Hepatology</i> , 2008, 47, 760-761.	7.3	0
635	Combination of Hepatitis B Viral Factors and Advanced Liver Disease in HBeAg-Negative Patients: The More, the Worse?. <i>Gastroenterology</i> , 2008, 134, 1270-1271.	1.3	0
636	Acute Fatty Liver of Pregnancy with Concurrent Acute Hepatitis B Virus Infection. <i>American Journal of Gastroenterology</i> , 2008, 103, 2663-2665.	0.4	0
637	Both insulin resistance and alanine aminotransferase level increase the risks of cardiovascular disease in fatty liver disease. <i>Hepatology</i> , 2009, 50, 989-989.	7.3	0
638	Carvedilol versus variceal band ligation for prevention of the first variceal bleed. <i>Hepatology</i> , 2010, 51, 718-719.	7.3	0
639	From liver markers to life expectancy. <i>Hepatology</i> , 2010, 51, 720-720.	7.3	0
640	616 HEPATITIS B GENOMIC VARIABILITY CORRELATES WITH INTRAHEPATIC VIRAL ANTIGEN EXPRESSION. <i>Journal of Hepatology</i> , 2010, 52, S242.	3.7	0
641	Alpha-fetoprotein in chronic hepatitis C. <i>Journal of the Formosan Medical Association</i> , 2011, 110, 730.	1.7	0
642	Uncovered issues in the overview of nonalcoholic steatohepatitis. <i>Journal of the Formosan Medical Association</i> , 2011, 110, 798.	1.7	0
643	Hepatitis during antituberculosis treatment. <i>Journal of the Formosan Medical Association</i> , 2011, 110, 801.	1.7	0
644	Reply to Guedj et al.: Early transient increase of hepatitis C virus viral load in genotype 1 and 2 infections, and the use of mathematical modeling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, E303-E303.	7.1	0
645	527 SUSTAINED HCV CLEARANCE AND INCREASED HBSAG SEROCLEARANCE IN PATIENTS WITH DUAL CHRONIC HEPATITIS C AND B POST-PEGINTERFERON ALFA-2A AND RIBAVIRIN TREATMENT: A 5-YEAR FOLLOW-UP. <i>Journal of Hepatology</i> , 2012, 56, S209.	3.7	0
646	Hepatitis B virus mutants associated with hepatitis b surface antigen loss: Chicken or egg?. <i>Hepatology</i> , 2012, 55, 656-657.	7.3	0
647	Hepatitis B Virus Genotypes: Clinical Relevance and Therapeutic Implications. <i>Current Hepatitis Reports</i> , 2013, 12, 124-132.	0.3	0
648	P639 SPONTANEOUS SEROCLEARANCE OF HBsAg IN HEPATITIS B VIRUS/HEPATITIS C VIRUS DUALY INFECTED PATIENTS: A 10-YEAR FOLLOW-UP. <i>Journal of Hepatology</i> , 2014, 60, S281.	3.7	0

#	ARTICLE	IF	CITATIONS
649	P174 THE CRISPR/Cas9 SYSTEM FACILITATES ELIMINATION OF THE PERSISTENT INTRAHEPATIC HBV GENOMES IN VIVO. <i>Journal of Hepatology</i> , 2014, 60, S124.	3.7	0
650	P642 LOWER RISK OF CIRRHOSIS AND HEPATOCELLULAR CARCINOMA IN NON-DIABETIC CHRONIC HEPATITIS B PATIENTS WITH NEW ONSET HYPERLIPIDEMIA: A NATIONWIDE COHORT STUDY. <i>Journal of Hepatology</i> , 2014, 60, S282.	3.7	0
651	Reply to: Modulation of Toll-like receptor 9 expression on monocytes of viral hepatitis patients. <i>Antiviral Therapy</i> , 2014, 20, 669-670.	1.0	0
652	Sorafenib and SC-1 Exhibit Anti-fibrotic Effects Through Signal Transducer and Activator of Transcription 3 Inhibition. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1386.	4.4	0
653	Reply. <i>Hepatology</i> , 2016, 64, 1814-1814.	7.3	0
654	Genetic Variation in FCER1A Gene Predicts Sustained HBsAg Clearance in East-Asian Patients Treated with Pegylated Interferon Alfa-2a (40kd): The "Peg-Be-Yond" Study. <i>Journal of Hepatology</i> , 2016, 64, S603.	3.7	0
655	Long-Term Assessment of Renal Function in Patients following Antiviral Therapy for Chronic Hepatitis C Virus Infection. <i>Journal of Hepatology</i> , 2016, 64, S610.	3.7	0
656	Sofosbuvir-based all-oral regimens for patients with chronic hepatitis C genotype 2 infection: integrated analysis of eleven clinical studies. <i>Journal of Hepatology</i> , 2017, 66, S738-S739.	3.7	0
657	Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin in Asian patients with genotype 1b chronic hepatitis C virus infection and compensated cirrhosis: ONYX-II post-treatment week 24 results. <i>Journal of Hepatology</i> , 2017, 66, S532.	3.7	0
658	Sofosbuvir-Based all-Oral Regimens for Patients with Chronic Hepatitis C Genotype 2 Infection: Integrated Analysis of Eleven Clinical Studies. <i>Gastroenterology</i> , 2017, 152, S1095.	1.3	0
659	Letter: the influence of direct acting agents for hepatitis C, on hepatitis B reactivation. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 208-208.	3.7	0
660	IDDF2018-ABS-0106...Tenofovir alafenamide (taf) compared with tenofovir disoproxil fumarate (tdf) in patients with chronic hbv: week 96 efficacy and safety results in chinese patients enrolled in 2 global phase 3 studies. , 2018, , .		0
661	Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study. <i>Journal of Hepatology</i> , 2018, 68, S266.	3.7	0
662	High mortality rate in HBV-related cirrhosis patients with HEV superinfection. <i>Journal of Hepatology</i> , 2018, 68, S753.	3.7	0
663	Real-world rates of hepatitis B surface antigen seroclearance in patients with chronic hepatitis B: a systematic review, conventional aggregated data meta-analysis and individual patient data meta-analysis. <i>Journal of Hepatology</i> , 2018, 68, S478-S479.	3.7	0
664	THU-195-An open-label, randomized, active control trial of 8 versus 12 weeks of elbasvir/grazoprevir for naive chronic hepatitis C genotype 1b patients with mild fibrosis (EGALITE): Impact of baseline viral loads and NS5A resistance-associated substitution. <i>Journal of Hepatology</i> , 2019, 70, e248-e249.	3.7	0
665	Letter: contraindicated drug-drug interactions before and after initiation of direct-acting antiviral agents in chronic hepatitis C patients in Taiwan. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 115-116.	3.7	0
666	FRI-240-Comparison of Abbott RealTime HCV genotype II, Abbott HCV genotype plus RUO with Roche Cobas HCV genotyping assays for hepatitis C virus genotyping. <i>Journal of Hepatology</i> , 2019, 70, e500.	3.7	0

#	ARTICLE	IF	CITATIONS
667	Editorial: comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting anti-viral agents in chronic hepatitis C – authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 117-118.	3.7	0
668	IDDF2019-ABS-0168...Bone and renal safety are improved in chronic hbv patients 1 year after switching to tenofovir alafenamide (TAF) from tenofovir disoproxil fumarate (TDF). , 2019, , .		0
669	Large and middle hepatitis B surface antigen: the lower the better?. <i>Gut</i> , 2019, 68, 376-377.	12.1	0
670	Hepatobiliary and Pancreatic: Biliary hamartoma manifests as liver cysts. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 11-11.	2.8	0
671	Letter: hepatitis B virus infection and risk of multiple myeloma – a meta-analysis of cohort studies. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 310-311.	3.7	0
672	Reply to letter to the editor: Successful eradication of HCV by short-course DAAs in HCV positive donor to HCV-Negative recipient during Haplo-HSCT. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1719-1720.	1.7	0
673	Editorial: increasing burden of nonalcoholic fatty liver disease – a call to action. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1430-1432.	3.7	0
674	Response to letter to the editor – Factors predicting outcomes of hepatitis B-related cirrhosis patients with long-term antiviral therapy. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 915-917.	1.7	0
675	Reply to: – Sofosbuvir and the risk of kidney dysfunction. <i>Journal of Hepatology</i> , 2021, 74, 257-258.	3.7	0
676	510 PROGRESSION OF CHRONIC HEPATITIS B TO CIRRHOSIS AND HEPATOCELLULAR CARCINOMA BY AGE, SEX, DISEASE ACTIVITY, AND TREATMENT STATUS USING AASLD CRITERIA. <i>Gastroenterology</i> , 2021, 160, S-786.	1.3	0
677	Reply to – Tacrolimus concentrations were not affected by glecaprevir/pibrentasvir treatment for hepatitis C virus infection in an adult living donor liver transplant recipient with uremia. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 1410-1411.	1.7	0
678	Systemic therapy for hepatocellular carcinoma: New agents and therapeutic hierarchy. <i>Journal of the Formosan Medical Association</i> , 2021, , .	1.7	0
679	IDDF2021-ABS-0080...96-week efficacy and safety of tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) switch vs. continued TDF treatment among virologically-suppressed hepatitis B patients of asian ethnicity. , 2021, , .		0
680	Management of non-alcoholic fatty liver disease in patients with sarcopenia. <i>Expert Opinion on Pharmacotherapy</i> , 2021, , 1-13.	1.8	0
681	Strategies for hepatitis C virus treatment failure. <i>Journal of the Formosan Medical Association</i> , 2021, , .	1.7	0
682	Interspousal transmission of TT virus: Low efficiency and lack of apparent risk factors. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, 1287-1291.	2.8	0
683	The Impact of p53 Mutations on the Course of Hepatitis B or C-related Chronic Liver Diseases in Taiwan. <i>American Journal of Gastroenterology</i> , 2009, 104, S148.	0.4	0
684	Lower Alanine Aminotransferase Level and Higher Hepatitis B Viral Load at Baseline Correlate with Earlier Emergence of Lamivudine Resistance in Taiwanese Patients. <i>American Journal of Gastroenterology</i> , 2009, 104, S119.	0.4	0

#	ARTICLE	IF	CITATIONS
685	BRIEF COMMUNICATION: Efficacy of ribavirin plus interferon $\lambda$ ± on viraemia of GB virus-C/hepatitis G virus: Comparison with interferon $\lambda$ ± alone. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1998, 13, 1249-1253.	2.8	0
686	Hepatocellular carcinoma recurrence after interferon-free direct acting antiviral treatment for chronic hepatitis C virus infection: fact or fiction?. <i>Translational Cancer Research</i> , 2016, 5, S192-S195.	1.0	0
687	Letter to the editor: New kid in the playground: HBcrAg and risk of HCC. <i>Hepatology</i> , 2022, 75, 760-761.	7.3	0
688	IDDF2020-ABS-0058...48-week safety and efficacy of switching to tenofovir alafenamide (TAF) from tenofovir disoproxil fumarate (TDF) in chronic HBV asian patients with TDF risk factors (RF)., 2020, , .		0
689	Response to "ælodized Oil CT-Guided Radiofrequency Ablation for Hepatocellular Carcinoma Within Milan Criteria": <i>Hepatology International</i> , 2022, 16, 209.	4.2	0
690	Highlights. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 575-579.	1.7	0
691	Sofosbuvir-based direct-acting antivirals for patients with decompensated hepatitis C virus-related cirrhosis. <i>Journal of the Chinese Medical Association</i> , 2022, Publish Ahead of Print, .	1.4	0
692	Looking Into the Crystal Ball: A Novel Biomarker for Outcomes of Patients With Chronic Hepatitis B Virus Infection. <i>Hepatology Communications</i> , 2022, 6, 5-7.	4.3	0
693	Highlights. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 871-875.	1.7	0
694	Letter: elevated aspartate aminotransferase and aspartate aminotransferase to alanine aminotransferase ratio predicts poor survival in hepatocellular carcinoma after resection" Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1764-1764.	3.7	0